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microRNA-433 Inhibits Glucocorticoid and TGF-β Signaling: Impacts 
on Osteoblast Circadian Rhythm, Commitment, and Differentiation 
 
Spenser S. Smith, Ph.D. 
University of Connecticut, 2016 
 
Lineage commitment and differentiation of skeletal cells requires coordinated 
regulation of multiple signaling systems by microRNAs (miRNAs). Transforming growth 
factor β (TGFβ) is important for osteoblastogenesis, chondrogenesis and adipogenesis. 
Here, we show that miR-433 limits TGFβ signaling and is a negative regulator of 
osteoblastogenesis and chondrogenesis. miR-433 has also been found to target the 
glucocorticoid receptor, and rhythmic secretion of glucocorticoids is critical for 
synchronizing circadian clocks. We hypothesized that miR-433 regulates the circadian 
clocks by regulating glucocorticoid signaling. 
 
In vivo, miR-433 displays robust rhythmicity in mouse calvaria. Its expression 
pattern was anti-phasic in relation to Bmal1, peaking after light removal. To determine if 
miR-433 regulates circadian rhythm in vitro, its activity was inhibited using a miR-433 
competitive inhibitor (miR-433 decoy) in stably transduced C3H/10T1/2 cells. miR-433 
inhibition modestly affected Bmal1 rhythm and it dramatically altered the phase of Per2. 
Inhibiting miR-433 activity amplified the glucocorticoid responsive genes Dusp1 and Per2, 
and induced nuclear localization of the glucocorticoid receptor. In vivo inhibition of miR-
433 activity using a Col1a1 driven miR-433 decoy transgenic model altered the phase 
and amplitude of the circadian clocks. Overall, we found that miR-433 displays a circadian 
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rhythm in calvaria, alters the phase of circadian clocks, and regulates sensitivity to 
glucocorticoids. 
 
BMSCs cultured in osteogenic medium caused a progressive decline in miR-433. In 
contrast, miR-433 was dramatically increased in BMSCs and iPSCs cultured in 
micromass to induce chondrogenesis. miR-433 levels remained constant during 
adipogenesis. miR-433 decoy cells were differentiated with BMP2 and miR-433 inhibition 
induced alkaline phosphatase, Runx2, and osteocalcin mRNAs. In micromass cultures 
treated with BMP2 and TGFβ, miR-433 inhibition promoted expression of chondrogenic 
mRNAs, Sox9 and Col2a1. In cells treated with an adipogenic cocktail, miR-433 inhibition 
failed to alter adipogenic gene markers or Oil-red O staining.  
 
Bioinformatic analyses suggested that miR-433 might target critical components of the 
TGFβ pathway. miR-433 inhibition amplified TGFβ signaling, evidenced by increased 
activity of a TGFβ-responsive SBE4 luciferase reporter and enhanced TGFβ-induced 
pSMAD2. To determine underlying mechanisms, we used Luciferase-3’UTR reporter 
assays, and experimentally validated SMAD2 and TGFBR1 as novel miR-433 targets. 
Overall, miR-433 attenuates TGFß signaling, and restrains osteoblastic and 
chondrogenic differentiation. 
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CHAPTER 1 
Introduction:  
Bone Formation, Circadian Rhythm, and Lineage Commitment of 
Mesenchymal Stem Cells 
 
Bone Formation 
The skeleton forms through two distinct processes, endochondral and 
intramembranous ossification. The skull, clavicle, and sternum form through 
intramembranous ossification, a process by which mesenchymal precursors directly 
differentiate into osteoblasts. The appendicular skeleton forms through endochondral 
ossification, a developmental process whereby a cartilage template is gradually replaced 
by bone. Bone, itself, is a highly dynamic tissue that is continuously remodeled, in a tightly 
regulated cycle of coupled osteoclast-mediated bone resorption followed by osteoblast-
mediated bone formation. This is the only process whereby adults can renew bone tissue, 
and it is also critical for mineral homeostasis. Prevalent skeletal diseases, such as 
osteoporosis, are caused by an imbalance in bone remodeling. Osteoporosis is a major 
metabolic bone disease affecting 10 million adults in the United States and results in an 
estimated annual health care cost of $20 billion (1-3). It is characterized by reduced bone 
mineral density and deterioration of the bone microarchitecture as a result of disrupted 
remodeling, therefore increasing risk of fracture. 
 
Osteoblasts 
Osteoblasts are the cells within the skeleton that are responsible for bone 
formation. Osteoblasts differentiate from a multi-potential mesenchymal progenitor cell in 
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response to pro-osteogenic signaling molecules, including transforming growth factor β 
(TGF- β), bone morphogenetic proteins (BMPs), and Wnts (Figure 1.1). During early bone 
formation, osteoprogenitors are recruited to the bone formation surface and proliferate. 
Further maturation initiates synthesis and secretion of extracellular matrix proteins, the 
most abundant protein being type I collagen. Early osteoblasts express many factors, 
including alkaline phosphatase (AP), an enzyme that plays a role in matrix mineralization. 
Osteoblasts also synthesize non-collagenous bone matrix proteins, including bone 
sialoprotein, osteopontin, osteonectin, and osteocalcin (Figure 1.1). These proteins play 
an important role in maintaining bone mineral homeostasis and bone metabolism (4).  
 
During the early stages of osteogenesis, many osteogenic transcription factors are 
induced, including the key transcription factor Runt related transcription factor 2 (Runx2), 
as well as Osterix (Figure 1.1). Runx2-deficient mice display defects in skeletal 
development, and lack ossification due to arrested osteoblast differentiation (5,6). Osterix 
is downstream of Runx2, and Osterix-null mice also lack bone formation despite formation 
of a cartilagenous skeleton (7). During later osteogenesis, bone sialoprotein and 
osteocalcin are induced, and the extracellular matrix matures and becomes mineralized. 
Following terminal differentiation, several fates await osteoblasts. They can become bone 
lining cells or become osteocytes or can undergo apoptosis. Bone lining cells are flat cells 
lining bone surfaces, and are believed to signal osteoclasts and osteoblasts to initiate 
bone remodeling, and are therefore important in maintaining the overall structural integrity 
of bone (reviewed by (8)). Osteocytes are dendritic cells that become embedded within 
the mineralized matrix of bone. Osteocytes primarily function as the bone 
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mechanosensors and can release signaling molecules to induce bone remodeling or 
initiate repair for damaged bone (9). Although the role of osteocytes is still not completely 
understood, they are thought to regulate bone mass, regulate phosphate metabolism, 
and even resorb bone.   
 
Figure 1.1. Lineage commitment of mesenchymal stem cells. Diagram illustrating 
the lineage commitment of mesenchymal stem cells towards osteoblasts, 
chondrocytes, and adipocytes, including key differentiation factors and lineage marker 
genes.   
 
Adipocytes 
Osteoblasts differentiate from a common multi-lineage precursor cell which can be 
directed by differential signaling molecules towards alternate lineages, including 
adipocytes or chondrocytes. Signals important for specifying lineage choice play an 
important role in the regulation of bone mass, as signals promoting the differentiation of 
progenitors down the alternate lineages tend to be negative regulators of 
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osteoblastogenesis. For example, Wnt6, Wnt10a, Wnt10b are well established promoters 
of osteogenic differentiation and restrain adipogenesis (10). For adipogenic 
differentiation, CCAAT enhancer binding protein α (Cebpα) and peroxisome proliferator 
activated receptor gamma (Pparγ) are critical adipogenic transcription factors and are 
potent repressors of osteoblastic commitment (Figure 1.1) (reviewed by (11)). Cebpα and 
Pparγ initiate transcriptional activation of several adipogenic genes and permanently 
arrest growth of these cells to allow for the development of a fully differentiated phenotype 
(reviewed by (11)). Adipocytes play a vital role in energy homeostasis and are the largest 
reservoir of triglycerides in the body. Insulin and glucocorticoids are major signaling 
molecules that promote the expansion of adipocytes (reviewed by (11)). Mature 
adipocytes are characterized by the expression of fatty acid binding protein 4 (Fabp4), 
and form large lipid droplets within the cell (reviewed by (11)).  
 
Chondrocytes 
Chondrocytes are the cells responsible for cartilage formation. Cartilage is critical 
for bone development in the process of endochondral ossification, but also plays 
important roles in repair and as mechanoabsorbers for joints. Repair of fractured bone 
mirrors bone formation, so chondrocytes also play a critical role in the repair process. 
 
Cartilage formation begins with the condensation of mesenchymal stem cells, 
which then become closely packed together, and mature towards chondrocytes. 
Osteochondral progenitors proliferate and begin expressing Sox9, the master 
transcriptional factor that promotes the commitment of mesenchymal progenitors to the 
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chondrogenic lineage (Figure 1.1). Sox9 promotes the proliferation and survival of 
mesenchymal cells, as well as stimulating the expression of cartilage matrix proteins, 
including type II collagen. Sox9 deficient mice have shortened limbs and the lack of Sox9 
disables the ability of mesenchymal cells to condense, therefore altering subsequent 
cartilage and bone formation (12). However, Sox9 can also inhibit chondrocyte 
hypertrophy and prevent vascularization of the cartilage template (13).  
 
As differentiation progresses, the rate of proliferation decreases and cells become 
flattened and pre-hypertrophic. Chondrocytes will synthesize proteoglycans and type II 
collagen, which remains sustained throughout chondrogenesis. Terminal differentiation 
of chondrocytes results in hypertrophy, where chondrocytes calcify their matrix and 
vascular invasion occurs. Hypertrophic chondrocytes dramatically increase their size and 
volume. Hypertrophic chondrocytes also express the transcription factor Runx2, which 
promotes the synthesis of the hypertrophic cartilage matrix protein type X collagen. Runx2 
also promotes the expression of vascular endothelial growth factor (Vegf), which is critical 
for blood vessel invasion and the replacement of the mineralized cartilage matrix with 
bone (14).   
 
TGF-β Signaling in Bone Marrow Stromal Cell Lineage Commitment 
The transforming growth factor ß (TGF-ß) superfamily is involved in a diverse array 
of cellular processes, including mesenchymal stem cell differentiation. The TGF-ß family 
contains three isoforms, ß1, ß2, and ß3, with ß1 being the most abundant. Across many 
tissues, TGF-ß plays a major role in promoting cell proliferation, as well as cell survival, 
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migration, and production of extracellular matrix (15-20). TGF-β signaling is initiated upon 
ligand binding to a cell surface receptor complex containing one type I and one type II 
TGF-β receptor. Ligand induced phosphorylation of type I receptor by the type II receptor 
activates receptor kinases, resulting in downstream phosphorylation of SMAD2 and/or 
SMAD3. These SMADs then dissociate from the receptor complex and associate with 
SMAD4, allowing for translocation into the nucleus and interaction with SMAD binding 
elements (SBEs) and other DNA binding proteins, to activate or repress gene 
transcription (reviewed by (21)).  
 
TGF-ß plays an important role in every stage of bone formation, and its function is 
context dependent (Figure 1.1). During early stages of differentiation, TGF-ß promotes 
chemotactic attraction of osteoblasts and osteoblast proliferation (22). Osteoblasts also 
secrete and deposit TGF-ß in the bone, which then gets released when osteoclasts resorb 
bone, to recruit osteoblasts to enable new bone formation (reviewed by (21)). However, 
TGF-ß inhibits terminal differentiation by suppressing alkaline phosphatase and 
osteocalcin, as well as mineralization ((15), reviewed by (23)). TGF-ß also opposes BMP-
2 actions during later stages of differentiation, causing SMAD3 to physically interact with 
Runx2 to repress its activity (24).  
 
TGF-β is a crucial mediator of chondrogenesis, promoting the commitment and 
recruitment of osteochondral progenitor cells (Figure 1.1) (reviewed by (25)). TGF-β 
promotes condensation and proliferation of osteochondral progenitor cells by stimulating 
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MAPK and Wnt signaling pathways (26-28). TGF-β induces expression of Sox9 and is a 
potent stimulator of proteoglycan and type II collagen synthesis (29,30). TGF-β stimulates 
the synthesis of type II collagen synthesis by initiating downstream signaling and complex 
formation of SMAD3 and SMAD4, which associates with a Sox9 protein complex to 
activate a type II collagen enhancer region (31). However, TGF-β can restrain 
chondrocyte hypertrophy by reducing extracellular matrix mineralization (reviewed by 
(25)).  The role of TGF-β in the pathogenesis in osteoarthritis has also gained much 
attention in recent years, where inhibition of TGF-β has been found to attenuate the 
degeneration of articular cartilage (32).  
 
Although the role of TGF-β in lineage commitment is complex and context dependent, 
it is an important mediator of both osteogenic and chondrogenic differentiation. By 
understanding the mechanisms regulating TGF-β signaling, such as post-transcriptional 
and post-translational regulation, we can better develop therapeutics to treat diseases 
such as osteoporosis or osteoarthritis.  
 
Circadian Rhythm 
The circadian rhythm is an internal timing mechanism important for orchestrating 
physiological homeostasis by coordinating behavioral and physiological patterns, as well 
as other functions. The circadian rhythm synchronizes key biological processes such as 
tissue repair and growth, maintenance of the immune response, and optimization of 
metabolism, maintaining overall health. The circadian rhythm is driven by a complex 
8 
 
interaction between the hypothalamic suprachiasmatic nucleus (SCN), also known as the 
central clock, and the peripheral circadian clocks. The SCN is the central oscillator that 
responds to environmental periodic cues such as light, eating patterns, and temperature. 
In response to these cues, the SCN entrains peripheral circadian clocks through 
stimulation of neural or hormonal signals (e.g. glucocorticoids) to enact their effects on 
target tissues (33). The entrainment of tissues throughout the body is crucial to optimize 
physiological processes to the light/dark cycle. 
 
In the central and peripheral tissues, the circadian rhythm is maintained locally by 
clock genes which interact through transcriptional/translational feedback loops. The main 
positive regulators are aryl hydrocarbon receptor nuclear translocator-like (Bmal1) and 
circadian locomotor output cycles kaput (Clock), which are negatively regulated by the 
period genes (Per1, Per2, Per3), the cryptochrome genes (Cry1, Cry2), and the regulator 
orphan nuclear receptor gene Rev-Erbα (Figure 1.2). Bmal1 and Clock form a 
heterodimer, and bind to E-box elements of target genes to rhythmically induce gene 
transcription, including the expression of Per and Cry. Per, Cry, and Rev-Erbα proteins 
can then translocate back into the nucleus where they repress Bmal1 transcription (Figure 
1.2). The positive feedback loop involves the rhythmic regulation of Bmal1 transcription, 
whose mRNA levels peak 12 hours out of phase relative to Per and Cry. As a result, 
Bmal1 mRNA levels fall, whereas Per and Cry mRNA levels rise (Figure 1.2). This 
interaction between the clock proteins determines the oscillatory expression of target 
genes and contributes to the rhythmicity of physiological systems.  
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Figure 1.2. Circadian clock transcriptional regulation. Diagram of circadian clock 
transcription feedback loops. Bmal1 and Clock form a heterodimer and bind to E Box 
elements in the DNA to drive transcription, including Per, Cry, and Rev-Erbα. In turn, 
Per, Cry, and Rev-Erbα can inhibit their own transcription as well as the transcription of 
Bmal1. This feedback loop ensures anti-phasic expression pattern of Bmal1 (red line) 
and the negative regulators Cry and Per (purple line), promoting rhythmic gene 
expression to affect physiology and behavior.  
 
Importance of Circadian Rhythm in Maintaining Skeletal Homeostasis 
A substantial fraction of genes throughout the body display a rhythmic pattern, with 
nearly 43% protein coding genes within 12 organs displaying rhythmic transcriptional 
expression (34). Within the skeleton, the circadian rhythm is critical to maintain normal 
homeostasis, especially in chondrocytes, osteoclasts, and osteoblasts. Several key 
osteogenic genes have a clear diurnal expression, such as Runx2, osteocalcin, and 
Insulin-like Growth Factor 1 (Igf1) (35,36). Current evidence suggests that the circadian 
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rhythm coordinates bone remodeling to occur at night. Markers of bone formation and 
resorption peak at night, with lower levels during the day. Serum osteocalcin, levels of 
which are associated with bone mineral density, as well as type I collagen, have the 
highest levels in pre-menopausal women at night (37,38). Moreover, murine calvarial 
organ cultures display circadian mineral deposition with bursts of mineralization occurring 
at night (39).   
 
To determine if clock genes directly regulate bone mass, one study targeted the 
negative clock regulators using Per1-/-;Per2-/- and Cry1-/-;Cry2-/- mice and examined their 
bone phenotype. The Per1-/-;Per2-/- and Cry1-/-;Cry2 mice display a high bone mass 
phenotype in both vertebrae and long bones, and the phenotype continued to intensify as 
the mice aged (40). These mice had increased bone formation rate (BFR), mineral 
apposition rate (MAR), and osteoblast proliferation (40,41). Bmal1-/- mice display a similar 
phenotype, with higher BFR, MAR, and increased osteoblast number (40). Although the 
circadian clocks play an important role in maintaining skeletal health, the molecular 
mechanisms whereby circadian clocks regulate the skeleton is still poorly understood. 
 
 Disturbance of circadian rhythm can occur when environmental cues are shifted, 
as is the case for jet lag, night shift work, or insufficient sleep. This can result in changes 
of circadian clock amplitude, period length, or frequency of expression, which leads to 
alterations in chromatin modification, gene regulation, cellular metabolism, and immune 
responses (42). In fact, a single night of sleep loss can result in epigenetic and 
transcriptional alterations in clock genes within metabolic tissues (43). Alterations of the 
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circadian clocks can impact the stability, amplitude, or period length of activity, therefore 
affecting circadian clock targets and impacting cell homeostasis (44). The peripheral 
clocks resynchronize at a slower pace compared to the central clock, leading to 
desynchronization of tissues and their physiological processes (45). Chronic desynchrony 
is associated with the development and progression of cardiovascular disease, cancer, 
mental illnesses, and severe metabolic disorders (45,46).  
 
In addition, disruption of circadian rhythm can negatively impact the skeleton, 
leading to increased risk of developing osteoporosis or fractures (47). Patients with 
obstructive sleep apnea, one of the most common sleep disorders, are 2.7 times more 
likely to develop osteoporosis (48-50). Self-reporting insomnia patients in Norway also 
showed an increased risk of developing osteoporosis (51). The functional outcome of low 
bone mass can be observed in the Nurses’ Health Study which found an increased risk 
of wrist and hip fracture in postmenopausal women working night shifts (52). At the 
molecular level, patients with a low bone mineral density and adult growth hormone 
deficiency are unable to produce circadian expression of parathyroid hormone (PTH), a 
known bone anabolic agent (53). A similar phenotype is observed in sleep deprived rats. 
In these animals, plasma levels of IGF1, a critical regulator of osteoblast proliferation and 
differentiation, were decreased by 30% (54). Sleep-deprived rats displayed reduced 
osteoid, decreased osteoblast number, and reduced bone mineral density (54). Overall, 
it is clear that disruptions to circadian rhythm can negatively impact bone health.  
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The importance of circadian rhythm on cartilage has also been well established. 
Chondrocyte proliferation within the growth plate has a diurnal pattern, with the largest 
growth occurring during the early morning (55). To examine if chondrocytes have a similar 
circadian clock pattern as other tissues, one group used a Per2:luc clock reporter mouse 
model and found that Per2 activity is highly rhythmic in articular cartilage, sternal 
cartilage, and in the femoral bone. Additionally, glucocorticoid treatment and temperature 
modifications were able to entrain the circadian clocks within cartilage tissue (56). 
Cartilage-restricted deletion of Bmal1-/- in mice (Col2-cre) results in shorter bone length 
and reduced body size compared to wildtype controls (57). One possible mechanism is 
altered diurnal expression of Indian Hedgehog (Ihh) protein in Bmal1-/- mice, an important 
regulator of chondrocyte differentiation (57). However, the phenotype of Bmal1-/- mice 
may also be due to altered circadian expression of multiple chondrocyte genes. In fact, 
microarray data from cartilage finds 615 genes (3.9% total transcripts in cartilage tissue) 
display circadian rhythmicity, including many genes involved in differentiation, 
extracellular matrix production, and apoptosis (56). 
 
Disruptions in circadian rhythms have also been linked to the development of 
osteoarthritis. Osteoarthritis is one of the most common joint disorders, characterized by 
a degeneration of the articular cartilage and damage to the joint extracellular matrix, 
where catabolic activity outpaces anabolic activity. The development of osteoarthritis has 
been linked to several risk factors, including age, mechanical injury, and chronic 
inflammation. One possible mechanism linking aging and the development of 
osteoarthritis is a disruption in circadian rhythms in cartilage tissue. Aged tissue showed 
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diminished amplitude of the circadian clocks (56). Additionally, Bmal1 deficient mice have 
damaged articular cartilage, with reduced levels of phosphorylated SMAD 2/3, as well as 
decreased expression of nuclear factor of activated T cells 2 (NFATC2), Sox9, aggrecan, 
and Col2a1 (58). Bmal1 is also important in maintaining energy homeostasis in articular 
cartilage. Bmal1 inhibits the expression of Sirt1, an NAD+ dependent deacetylase protein, 
which is repressed in osteoarthritis patients displaying induced Bmal1 levels (59). The 
rhythmic expression of anabolic and catabolic chondrocyte genes could play a role in 
maintaining the growth and repair of cartilage in sync with physical activity. 
 
The importance of circadian rhythm in osteoclasts is still being investigated. Bone 
resorption by osteoclasts displays a diurnal pattern with high levels occurring at night (60). 
Osteoclast-restricted knockdown of Bmal1 (Cathepsin K-cre) reduced bone resorption 
and increased bone formation (61). Additionally, Bmal1 controls the rhythmic expression 
of several osteoclastic genes, including nuclear factor of activated T cells (NFATC1), 
dendrocyte expressed seven transmembrane protein (DCSTAMP), and acid 
phosphatase 5 (Acp5) (61). Steroid receptor coactivator (SRC) can initiate transcription 
of Bmal1/Clock in osteoclasts to activate the Nfatc1 promoter, thus generating its rhythmic 
expression (61). As with other peripheral tissues, glucocorticoids have also been found 
to be a major regulator of osteoclast entrainment and rhythmic expression of tartrate-
resistance acid phosphatase (Trap), Nfatc1, and cathepsin K (62). However, much is still 
unknown about circadian clocks in osteoclasts. 
 
 
14 
 
Glucocorticoid Signaling 
The glucocorticoid receptor is encoded by the Nr3c1 gene, and can be alternatively 
spliced into multiple isoforms, of which GRα and GRβ are the most prominent. GRα is 
classically known as a transcriptional activator or repressor, and is found in the cytoplasm 
when not bound to ligand. GRβ is located in the nucleus and is thought to have a 
dominant-negative effect on GRα. In addition, it can act on a set of targets genes not 
regulated by GRα. GRα complexes with heat shock protein 90 (HSP90) and 70 (HSP70), 
non-receptor tyrosine kinases, and immunophilins within the cytoplasm (reviewed by 
(63)). Glucocorticoids pass through the plasma membrane where the bind to the 
glucocorticoid receptor, causing homodimerization and release from the inhibitory 
complex, opening its to conformation to expose the nuclear localization signal (reviewed 
by (63)).  
 
Heat shock proteins chaperone and translocate the ligand-bound glucocorticoid 
receptor to the nucleus. The glucocorticoid receptor then recruits coactivators and 
chromatin-remodeling complexes to interact with palindromic sequences termed 
Glucocorticoid Responsive Elements (GREs), found in promoters or within target genes, 
to activate transcription. Direct glucocorticoid receptor target genes include dual 
specificity phosphatase 1 (Dusp1), glucocorticoid induced leucine zipper (Gilz), and 
serum/glucocorticoid regulated kinase 1 (Sgk1) (reviewed by (64)). The glucocorticoid 
receptor can also indirectly regulate gene expression by recruiting other transcription 
factors (reviewed by (65)). In addition, the glucocorticoid receptor can target negative 
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GREs, recruiting corepressors nuclear corepressor 1 (NCoR1) and nuclear corepressor 
2 (NCoR2) to engage histone deacetylases, to repress transcription (reviewed by (63).  
 
The activity of the glucocorticoid receptor can be modified post-translationally by 
phosphorylation, acetylation, and SUMOylation. Phosphorylation of the glucocorticoid 
receptor by kinases including MAPK, cyclin-dependent kinase, and glycogen-synthase 
kinase-3 (GSK-3) occur post-ligand binding and have been reported to activate or repress 
activity (66,67). Acetylation of the glucocorticoid receptor impairs its activity, and its levels 
and acetylation are regulated in a circadian manner. Glucocorticoid receptor levels peak 
at night and dip in the morning, whereas acetylation of the glucocorticoid receptor peaks 
in the morning and is lowest at night, which increases cell sensitivity to glucocorticoids at 
night (68). Additionally, hyperacetylation of HSP90 can inhibit its activity and prevent 
nuclear localization of the glucocorticoid receptor (68). Moreover, SUMOylation of the 
glucocorticoid receptor have been shown to regulate its subcellular localization, 
organization of chromatin structure, and its overall stability (69).  
 
Glucocorticoids, among other hormones, are important entrainment signals that 
synchronize circadian rhythms in the kidney, liver, heart, and other tissues (70). The SCN 
acts as the master synchronizer in part by stimulating the release of glucocorticoids 
through the hypothalamic-pituitary-adrenal (HPA) axis (71,72). In humans, serum levels 
of glucocorticoids cycle, with their peak in the early morning, just before waking, and their 
lowest levels in the evening (73). The circadian clocks can be directly regulated by 
glucocorticoid signaling, as the glucocorticoid receptor transcriptionally activates 
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expression of Per1 through a GRE in its promoter, and Per2 through a GRE in the first 
intron (74-76). Indeed, oscillating levels of circulating glucocorticoids correspond to Per1 
mRNA levels in peripheral tissues (77).  
 
High levels of glucocorticoids can disrupt the circadian rhythm, and several 
disorders have been linked to altered glucocorticoids levels (reviewed by (78)). Patients 
with Cushing’s syndrome display high levels of endogenous glucocorticoids, have an 
altered daily rhythm and frequently experience sleep disorders such as sleep apnea or 
sleep fragmentation (reviewed by (78)). Patients with this disorder frequently have 
diabetes mellitus, hypertension and osteoporosis, as well as other secondary disorders 
and diseases (reviewed by (78)). 
 
The role of glucocorticoid signaling in bone is complex. Normal, endogenous 
glucocorticoids are critical for skeletal health (reviewed by (79)). Glucocorticoids can 
enhance the expression of osteoblast differentiation markers such as alkaline 
phosphatase, osteocalcin, and bone sialoprotein in vitro (reviewed by (80)). In contrast, 
excessive exposure of the skeleton to glucocorticoids leads to the development of 
osteoporosis, which is frequently seen in patients treated long term with glucocorticoids 
for autoimmune disorders, inflammatory disease or malignancy. Glucocorticoid excess 
causes bone loss due to decreased osteoblast activity, reduced osteoblast number, 
increased osteocyte apoptosis, and disruption of extracellular matrix production 
(reviewed by (81)). Osteocalcin, particularly the undercarboxylated form, is thought to be 
involved in glucose metabolism, modifying insulin secretion and sensitivity (82,83). Most 
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recently, it was shown that glucocorticoid-mediated suppression of osteocalcin synthesis 
in bone mediated at least some of the adverse effects of glucocorticoids on energy 
metabolism, such as increased adiposity, insulin resistance and glucose intolerance (84). 
 
 MicroRNAs (miRNAs, miRs) 
microRNAs (miRNAs) play a crucial role in osteoblasts by regulating multiple 
genes involved in osteoblast differentiation and function. miRNAs are short (19-25 
nucleotides) non-coding RNAs that bind specific target mRNA sequences, resulting in 
either mRNA degradation or translational suppression. Primary miRNAs (pri-miRNAs) are 
transcribed by RNA polymerase II or III and are processed by the Drosha-DiGeorge 
syndrome region gene 8 (DGCR8) complex to form precursor miRNAs (pre-miRNAs) 
(Figure 1.3; (85)). The Dicer complex cleaves the pre-miRNA allowing its incorporation 
into the RNA-induced silencing complex (RISC). Helicase mediates the unwinding of the 
miRNA complex and removal of the unselected strand. The RISC complex will then guide 
the mature strand towards the seed binding region of a target mRNA, frequently located 
in the 3’ Untranslated Region (UTR), ultimately suppressing translation or causing mRNA 
degradation. miRNA activity can be complex, with a single miRNA regulating several 
mRNAs, or multiple miRNAs regulating a single mRNA. 
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The general importance of miRNAs in osteoblast biology was first demonstrated in 
mice in which Dicer was deleted in mature osteoblasts. These mice displayed increased 
cortical and trabecular bone volume, as well as perinatal bone formation (86). However, 
it is critical to keep in mind that individual miRNAs may have a positive or negative effect 
on osteoblast differentiation and function. For example, miRNAs targeting the bone 
morphogenic protein (BMP) pathway, can decrease osteogenesis. Overexpression of 
miR-133 and miR-135 antagonizes BMP induction of alkaline phosphatase, osteocalcin, 
and Runx2 (87,88). In our lab, miR-29 was found to induce osteoblast maturation and 
 
Figure 1.3: miRNA biosynthesis. pri-miRNA are transcribed from DNA and cleaved 
by the Drosha/DGCR8 complex to form the precursor miRNA. The pre-miRNA is 
exported from the nucleus by Exportin. The Dicer complex cleaves the pre-miRNA into 
a 21 nucleotide duplex which is incorporated into the miRNA RISC complex where 
helicase unwinds the double stranded miRNA to form a mature strand and a 
complementary passenger stand. RISC allows binding of the miRNA to target mRNA 
to result in either mRNA degradation or a suppression of translation (85). 
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target negative regulators of the Wnt signaling pathway, providing a potential underlying 
mechanism (89-91).  
 
MicroRNA Regulation of Circadian Rhythm 
Increasing evidence suggests that post-transcriptional regulators are an essential 
component of circadian clock control and make significant contributions to mRNA 
rhythms. The expression of more than 1000 non-coding RNAs have been found to be 
rhythmic (34). Among these, miRNAs were shown to display circadian rhythmicity in 
tissues including the liver, retina and SCN (92,93). One microRNA has even been found 
to display diurnal variation in human breast milk (94).  
 
On a macro scale, the rhythmicity of miRNAs can be determined by the levels of 
Dicer, since it is important for processing the mature miRNA. Indeed, Dicer displays a 
robust and differential rhythmicity in a variety of tissues. In the SCN and bone marrow 
mononuclear cells (BMNC), Dicer expression peaks at ZT5, while in retina its expression 
peaks at ZT 21, and in liver at ZT 9 (95). However, in mice aged to 24 months or in mice 
with diabetes, the peak expression of Dicer was shifted in the liver and SCN, and was 
decreased in the retina and in BMNC (95). In BMNC, the shift in Dicer expression changed 
the anti-phasic expression pattern of miR-146a and miR-125a (95). In Dicer deficient 
mouse embryonic fibroblasts (MEFs), the period for rhythmic expression of circadian 
clock genes was shortened by 2 hours, which was attributed to miR-24, miR-29a, and 
miR-30a targeting of the 3’UTR of the Per2 and Per3 mRNAs (96). Another study 
examining Dicer deficient mice also revealed changes in the liver, with an increase in the 
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period of circadian clock gene expression, with the most dramatic effect observed on all 
Per mRNA isoforms (97). However, the overall changes on liver physiological function 
were not as substantial as those seen in MEFs, indicating tissue-specific effects of 
miRNAs on circadian rhythm or inherent differences in in vivo or in vitro systems.  
 
miRNAs can help maintain circadian rhythm; conversely, miRNA expression can 
be regulated by circadian outputs (98-101). miRNAs can reduce targets’ oscillation 
amplitude and alter frequency by interfering with temporal gene expression (102). 
miRNAs can directly regulate circadian clocks in multiple tissues, and much of the work 
on miRNA targeting of clock genes has been done in the SCN (98,100,103-108). For 
example, miR-191 inhibits Bmal1 in the SCN, while miR-181 targets Clock (99). 
Moreover, miR-142 also targets the 3’UTR of Bmal1 in the SCN, and its overexpression 
represses the rhythmic expression of Bmal1 (108). Additionally, miR-185 targets the 
3’UTR of Cry1 and helps maintain its rhythmic expression in the SCN (107). In fibroblasts, 
the miR-192/miR-194 cluster was shown to target the 3’UTR of each of the Period genes, 
and overexpression of this cluster caused secondary effects by shortening the period of 
Bmal1 expression (108). Lastly, miR-107 targets Clock in enterocytes, which are the cells 
that line the intestinal tract; inhibition of miR-107 leads to deregulation of the circadian 
clocks, altering the phase and amplitude of their expression (109).  
 
Circadian Clocks Regulate miRNA Rhythmicity 
Conversely, the circadian clocks can regulate the rhythmic expression of miRNAs. 
Theoretical computational analysis predicted that miR-219 and miR-132, 2 miRNAs 
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expressed in the brain, could potentially modulate the rhythmicity of the circadian clocks 
(110). Indeed, experimental analysis of these miRNAs show they play an important role 
in regulating the circadian rhythm in the SCN. Bmal1/Clock can induce expression of miR-
219 by direct binding to its promotor (111). In vivo antisense knockdown of miR-219 and 
miR-132 in the SCN results in a lengthened circadian period and a defective light-induced 
clock resetting (111). However, miR-132 was shown to work independently of Bmal1 and 
Clock regulation, and is instead regulated by the negative transcriptional regulators Cry1 
and Cry2 (111). 
 
miRNA Regulation of Liver Rhythmicity 
The impact of miRNA regulation of circadian rhythm is most apparent in the liver. 
The liver’s circadian rhythm is determined primarily by feeding patterns, and therefore its 
function is highly cyclical. Liver metabolism is under circadian control, with glucose, bile 
acids, lipids, and cholesterol displaying diurnal patterns (112). RNA sequencing studies 
of liver from mice kept under a 12 hour light/dark cycle revealed that the liver has 1,160 
oscillating protein coding transcripts, composing approximately 10% of the total genes 
(92,99). Interestingly, 373 of the transcripts had highest expression in the evening, while 
301 transcripts were high in the morning, corresponding to murine feeding patterns (92). 
RNA sequencing also revealed that the liver had 54 miRNAs that were expressed in a 
circadian manner, including miR-33, let-7, miR-103, and miR-122, many of which have 
been shown to impact liver function (92).  
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The miR-122 locus is highly expressed and is regulated by the circadian clocks 
(113-115). The pri and pre-miRNA forms of miR-122 display rhythmic expression in 
murine liver, with peak expression early in the morning (115). However, despite this 
pattern, mature miR-122 expression does not change throughout the day, suggesting 
differences in stability between the mature and pri and pre-miRNA forms (115). The miR-
122 promoter contains 2 regions under the control of Rev-erbα, with Rev-erbα deficient 
mice showing an inability to produce cycling miR-122 (115). Conditional knockdown of 
liver miR-122 results in substantial alterations in several rhythmic mRNAs, with changes 
in amplitude, magnitude, and phase, especially in cholesterol and lipid metabolism genes 
(115). For example, peroxisome proliferator-activated receptor β/δ (Pparβ/δ) and the 
Pparα coactivator Smarcd1/Baf60a (Swi/Snf-related, matrix-associated, actin dependent 
regulator of chromatin, subfamily d, member 1/Brg1-associated factor 60a) were directly 
targeted by miR-122 in the 3’UTR (115).   
 
Moreover, miR-122 targets Nocturnin, a key deadenylase highly rhythmic in liver. 
Mice deficient in Nocturnin have altered lipid metabolism (116). Anti-sense 
oligonucleotide knockdown of miR-122 activity in the liver increased Nocturnin amplitude 
and heightened its expression at night, suggesting that miR-122 mediates its rhythmic 
expression (117). In turn, Nocturnin influences the rhythmic expression of other genes, 
such as Igf1, which could potentially regulate the clock output pathway to impact tissue 
function. Overall, miR-122 appears to be a potent modulator of circadian output pathways 
that can alter liver homeostasis. The circadian expression of miRNAs in the liver impacts 
the regulation of their targets, thereby affecting liver physiology and metabolism. 
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MicroRNA Regulation of Circadian Rhythm in the SCN 
The suprachiasmatic nucleus is the master synchronizer of the circadian clocks, 
and as such, is a highly rhythmic tissue that is under miRNA regulation. miR-132 displays 
robust rhythmicity within the SCN, with its expression increasing after exposure to light 
(111). The expression of miR-132 is regulated by the MAPK and CREB pathways (111). 
In vivo knockdown of miR-132 activity increases SCN sensitivity to light, revealing miR-
132 as a negative regulator of light entrainment (111). Overexpression of miR-132 alters 
mouse behavior by diminishing wheel-running activities and shifting their phase in 
response to light (98). miR-132 regulates the circadian clocks response to light by 
targeting chromatin and translational regulators. miR-132 directly targets Mecp2, a CpG 
repeat binding protein, a chromatin regulator, p300, and Jarid1a, a translational regulator, 
in vitro and in vivo (98). miR-132 also inhibits the translational regulators Btg2 and Paip2a 
(98). Overexpression of Mecp2 increased promoter activity of Per1 and Per2, indicating 
a potential mechanism whereby miR-132 could regulate entrainment (98). In turn, mice 
deficient for the translational regulator Paip2a have reduced expression of the Period 
genes (98). Most interestingly, Paip2a and Btg2 can feedback on Period transcripts to 
accelerate their decay (98). Taken together, these results suggest a highly interconnected 
transcriptional and post-transcriptional loop involving the circadian clocks, miR-132, and 
miR-132 target genes.  As a result, miR-132 can alter entrainment of the SCN, thereby 
potentially affecting downstream synchronization of peripheral tissues throughout the 
body. In addition, miR-132 actions can modify chromatin remodeling and translation 
within the SCN.  
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miRNA Regulation of Circadian Rhythm in the Immune System 
Like many other physiological functions, innate immunity is under circadian control. 
The immune response fluctuates during different times of the day, altering immune cell 
number, cell movement, and cytokine production to match peak activity within the 
organism. This allows the immune system to coordinate the inflammatory response to 
times when pathogen exposure is higher, improving immune efficiency and recovery 
(118). The expression of miR-155, a pro-inflammatory microRNA, and miR-146, an 
immune repressor, appear to help mediate the rhythmic immune response. miR-155 
expression increases at night, correlating with the active phase in mice (119). In response 
to lipopolysaccharides (LPS), the transcription factor ETS2 induces miR-155 expression 
(119,120). Additionally, miR-155 is suppressed by interleukin-10 (IL-10), and IL-10 is 
under circadian control as its expression is induced by Bmal1 (119,120). miR-155 
suppresses Bmal1 in myeloid cells and inhibits Bmal1-mediated repression of nuclear 
factor κB (NF-κB) and TNFα (119). Inhibition or overexpression of miR-155 also alters the 
phase of Bmal1 expression and ablates the cytokine response to LPS (119). Overall, the 
innate immune system, in response LPS exposure, can induce miR-155 expression to 
downregulate Bmal1, thereby activating an inflammatory response by myeloid cells.  
 
Additionally, chronic inflammation can disrupt circadian rhythm, which has been 
linked to the pathogenesis of diabetic retinopathy and the alteration of miR-146 
expression (121). In diabetic rats, Bmal1 amplitude is markedly increased while Per1 
expression is repressed, when compared to non-diabetic rats (121). Whereas non-
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diabetic rats exhibited oscillatory expression of miR-146 in retinas, rhythmicity was 
ablated in diabetic rats (121). miR-146 directly targets IL-1 receptor-associated kinase 1 
(Irak1), a pro-inflammatory cytokine, and the expression pattern of these 2 genes is anti-
phasic. In diabetic rats, Irak1 rhythmic expression was also ablated (121). In humans, 
Irak1 expression was upregulated in diabetic patients, increasing downstream 
intracellular adhesion molecule 1 (Icam-1) activity, which alters monocyte adhesion and 
leukocyte migration (121). Overall, microRNAs can modulate the immune response by 
regulating rhythmic expression of target genes. 
 
miRNA Regulation of Circadian Rhythm During Development 
Although understudied, there is evidence that miRNAs can regulate developmental 
processes. One study used deep sequencing to examine the miRNA profile in chickens 
before and after gonad development; 144 miRNAs were found to be induced or 
decreased within the hypothalamus, the region that hosts the SCN (122). 15 of the most 
differentially expressed miRNAs during gonad development were predicted to target 7 
circadian clock genes, including Per2, Bmal1, Bmal2, Clock, and Cry1/2 (122). Circadian 
clock genes show significant upregulation following gonad development. It is important to 
note that the impact of the circadian clocks during development is still vastly unknown, 
and therefore potential interpretations of the impact of miRNAs are still limited.  
 
Clinical Implications 
miRNA regulation of circadian rhythms has potential clinical implications. For 
example, there are no reliable non-invasive tests for diagnosing women with 
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endometriosis, and as a result, many women presenting with pelvic pain undergo a 
laparoscopy. In healthy patients, circulating plasma levels miR-200a and miR-141 
increase in the evening (123). However, patients with endometriosis were unable to 
generate circadian expression of miR-200a and miR-141, with suppressed expression 
during the evening (123). These findings support the concept that serum levels of these 
miRNAs may potentially be used as biomarkers for diagnosing endometriosis, although 
further research is needed.  
 
Recently, miR-182 has been implicated in a circadian rhythm disorder in neonatal 
patients with hypoxic-ischemic brain damage (HIBD) (124). In patients with HIBD, there 
is a significant upregulation of circadian clock protein levels but no change in mRNA 
expression within the pineal gland. Administration of miR-182 agonists or mimic in the 
pineal gland inhibited Clock protein expression, whereas oxygen deprivation of 
pinealocytes downregulated miR-182 expression, increasing Clock protein levels (124). 
This study suggested that miR-182 may be a potential therapeutic target to restore 
circadian rhythms in patients with HIBD (124).  
 
Within the brain, miR-96 could potentially be targeted to protect the nervous 
system from damage caused by oxidative stress. miR-96 displays a diurnal rhythm and 
inhibits glutathione production, a well-established anti-oxidant which protects against 
oxidative stress (125). miR-96 targets the 3’UTR of cysteine transporter excitatory amino 
acid carrier 1 (EEAAC1), an important transporter of the amino acid cysteine, which is 
considered a major determinant for glutathione synthesis in neurons (125). Glutathione 
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and reactive oxygen species display anti-phasic expression patterns in the 
mesencephalon and SCN, which could be modulated by miR-96 activity (125). Since 
there is not current therapeutic method of inducing glutathione production, a miR-96 
antagomir could potentially be a future option.  
 
Although the function and impact of many miRNAs on circadian clock output 
pathways have been examined in many cell types in vitro, their impact in vivo is still vastly 
understudied. Therefore, the overall importance of miRNAs on circadian rhythm in 
animals not well understood. In our research, we aim to elucidate the role of a specific 
miRNA in regulating the circadian clocks in vitro and in vivo, in osteoblasts and other 
skeletal cells.  
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CHAPTER 2 
 
Research Aims and Hypotheses 
miRNA regulation of circadian rhythm in the skeleton has not been reported. 
However, microRNA-433 (miR-433) was shown to target the glucocorticoid receptor 3’ 
UTR within the adrenal gland (126). Rhythmic secretion of glucocorticoids is critical for 
synchronizing local clocks in peripheral tissues, in part by activating transcription of Per 
genes (127). Moreover, as circulating glucocorticoid levels fluctuate diurnally, so does the 
sensitivity of tissues to glucocorticoids (128). We hypothesize that miR-433 helps 
maintain circadian rhythm in osteoblasts by regulating glucocorticoid signaling, potentially 
altering skeletal homeostasis. 
Additionally, preliminary data suggest that miR-433 could alter lineage 
commitment in the skeleton. Previously, our lab found that miR-433 could differentially 
target a single nucleotide polymorphism (SNP) in osteonectin (SPARC). This SNP was 
associated with bone mass in men with idiopathic osteoporosis and caused changes in 
bone mass in a knock-in mouse model (129-134). In human cells, inhibition of miR-433 
activity enhanced expression of the osteoblast marker genes alkaline phosphatase and 
osteocalcin (134). Additionally, a mutation in the miR-433 binding site in histone 
deacetylase 6 (HDAC6) is associated with a form of X-linked chondrodysplasia (135). 
However, the function of miR-433 in chondrogenesis has not been established. 
Bioinformatic analyses suggested that miR-433 might target critical components of the 
TGF-β signaling pathway. Since TGF-β signaling is important for differentiation of 
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osteoblasts and chondrocytes, we hypothesized that miR-433 would inhibit differentiation 
of these cells. 
Aim 1: Determine if miR-433 displays rhythmic expression in vivo and in vitro and 
whether it regulates circadian clocks 
miRNAs can regulate osteoblast circadian rhythm through several mechanisms: 
direct inhibition of the circadian clocks, regulation of entrainment, or through targeting 
rhythmic osteoblastic genes. Previous studies have shown that miRNAs can display 
circadian expression patterns in a tissue specific manner, therefore potentially impacting 
the rhythmic expression of their mRNA targets. To elucidate the role of miR-433 on 
circadian rhythm, we will determine if it is under circadian regulation in the skeleton. To 
understand if miR-433 is involved in regulating circadian rhythm, we will develop an in 
vitro model of synchronized osteoblast progenitor cells, and correlate miR-433 expression 
with what is observed in vivo.  
 
A: Examine calvarial miR-433 expression in mice maintained in a 12 hour light/dark 
cycle  
To examine whether miR-433 displays circadian rhythmicity in the skeleton, we will 
examine miR-433 expression in the calvaria. Previous studies have shown calvaria to be 
an excellent model for circadian research within the skeleton (39,136). We will examine 
miR-433 expression in calvaria from C57Bl/6 mice kept under a 12 hour light/dark cycle. 
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Samples will be characterized based on their Zeitgeber times (ZT), with ZT0 indicating 
the beginning of light exposure and ZT12 as light removal. RNA will be extracted and 
analyzed by qRT-PCR. Bmal1 and Per2 mRNA expression will be used as markers of 
circadian rhythm. Previous reports show that Bmal1 and Per have anti-phasic expression, 
where Bmal1 expression is high and Per expression is low at the beginning of a circadian 
day. miR-433 expression will be examined and compared to clock gene expression, as 
well as other potentially rhythmic miRNAs, miR-29 and miR-30. Gene expression will be 
analyzed for amplitude, frequency, and period length using previously published methods 
(137). We anticipate that miR-433 will be regulated in a circadian manner.  
 
B: Develop an in vitro model to study circadian rhythm and examine miR-433 
rhythmic expression in osteoblast precursor cells. 
To study the potential mechanism of miR-433 regulation on circadian rhythm, we 
will develop an in vitro model utilizing C3H/10T1/2 cells, a mesenchymal-like cell line 
previously shown to differentiate along the osteoblastic, chondrogenic, and adipogenic 
lineages (138,139). C3H/10T1/2 cells will be synchronized by a short pulse with the 
synthetic glucocorticoid dexamethasone, a well-established method for synchronizing 
cells and for studying circadian rhythm in vitro (140-143). We anticipate miR-433 
expression will display rhythmic expression. However, it is also possible that miR-433 
expression is regulated by systemic factors not present in vitro.  
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C: Knockdown miR-433 activity in synchronized C3H10T1/2 cells and determine the 
impact on the expression of circadian clock genes. 
The impact of miR-433 on the circadian clocks will be determined by measuring 
Bmal1 and Per2 mRNA expression in synchronized C3H/10T1/2 cells stably transduced 
with an inducible miR-433 decoy and a non-targeting decoy. We will use a previously 
described inducible knockdown (pSLIK) system that allows for tight regulation of 
transgene expression through control of the tet responsive promoter (TRE) (144). Cells 
will be transduced and pools of stably transfected cells selected using hygromycin. To 
achieve knockdown of miR-433 activity, we will use a miR-433 tough decoy (TuD) in which 
the green fluorescent protein (GFP) reporter gene carries 2 miR-433 binding sites in its 
3’UTR (145). When transcribed, the miR-433 tough decoy will act as a competitive 
inhibitor for endogenous miR-433, therefore relieving suppression of its targets. As a 
control, C3H/10T1/2 cells will be transduced with a non-targeting C. elegans tough decoy 
construct.  
C3H/10T1/2 miR-433 and non-targeting decoy cells will be synchronized using 
dexamethasone and treated with or without the tetracycline Doxycycline (Dox). Cells will 
be harvested every 6 hours for a 48 hour period. Bmal1 and Per2 mRNA expression will 
be quantified by qRT-PCR. Rhythmicity will be examined for changes in amplitude, period 
length, frequency, and phase of expression. We predict that miR-433 inhibition will disrupt 
the rhythmic expression of both Bmal1 and Per2. We hypothesize that miR-433 may 
promote Bmal1 expression and activity through suppressing expression of its negative 
regulator, Per2. Therefore, miR-433 knockdown could result in induced amplitude, 
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frequency, and period length of Per2 expression, with the opposite effect for Bmal1 
expression. 
 
Aim 2: Determine miR-433 regulation of glucocorticoid signaling and its impact on 
circadian rhythm.  
miR-433 was recently shown to target the glucocorticoid receptor (Nr3c1) 3’UTR, 
and rhythmic secretion of glucocorticoids is critical for synchronizing local clocks in 
peripheral tissues, in part by activating transcription of Per genes (126,127). Moreover, 
as circulating glucocorticoid levels fluctuate diurnally, so does the sensitivity of tissues to 
glucocorticoids (128). We hypothesize that miR-433 maintains circadian rhythm in 
osteoblasts by regulating glucocorticoid signaling. 
A: Determine if miR-433 inhibition increases Nr3c1 protein expression and affects 
sensitivity to glucocorticoids. 
To examine if miR-433 affects glucocorticoid sensitivity in cells of the osteoblastic 
lineage, stably transduced C3H/10T1/2 cells expressing a miR-433 decoy will be treated 
with several doses of dexamethasone. Glucocorticoid treatment directly activates Dusp1 
and Per2 transcription within minutes to hours of treatment, making them excellent 
markers for glucocorticoid signaling (127,146). Since miR-433 targets the glucocorticoid 
receptor, we expect miR-433 inhibition to increase Nr3c1 protein, which may augment 
expression of Dusp1 and Per2 after treatment with glucocorticoids. We will also examine 
temporal changes of Dusp1 and Per2 after dexamethasone treatment in the presence of 
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miR-433 inhibition. A non-targeting C3H/10T1/2 stably transduced cell line will be used 
as a control. Ultimately, altering glucocorticoid signaling could interfere with 
synchronization of the cells, thereby influencing the circadian rhythm and osteoblast 
function.  
Aim 3: Determine miR-433 regulation of mesenchymal stem cell lineage 
commitment towards osteoblasts, adipocytes, or chondrocytes. 
Lineage commitment and differentiation of skeletal cells requires coordinated 
regulation of multiple signaling systems by miRNAs. In silico analysis suggested that miR-
433 may target important components of the TGF-β pathway, which is important for 
osteoblastogenesis, chondrogenesis and adipogenesis. We will use transduced 
C3H/10T1/2 miR-433 and non-targeting decoy cells to examine the role of miR-433 in 
regulating TGF-β signaling, as well as lineage commitment. 
A: Determine whether miR-433 targets TGF-β pathway components and inhibits 
signaling. 
 To examine if miR-433 inhibits TGF-β signaling, we will use the C3H/10T1/2 cell 
line transfected with a construct carrying a luciferase reporter gene driven by a TGF-β 
responsive promoter (SBE4), along with a non-targeting and miR-433 inhibitor. Cells will 
be treated with vehicle or TGF-β1 and luciferase activity will be measured. We will confirm 
our results with C3H/10T1/2 non-targeting and miR-433 decoy cells, using the same 
reporter construct. Additionally, we will examine the activity of miR-433 on the 3’UTR of 
components of the TGF-β pathway predicted to be miR-433 targets (TGFBR1, TGFBR2, 
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SMAD2, and SMAD4) using a series of luciferase-3’UTR reporter assays. Protein levels 
of SMAD2 and SMAD2 phosphorylation will also be measured in response to vehicle or 
TGF-β treatment in miR-433 decoy cells, to examine potential regulation by miR-433. We 
anticipate miR-433 to inhibit TGF-β signaling by targeting multiple members in the 
pathway. 
B: Inhibit miR-433 activity and determine effect on lineage commitment and 
expression of differentiation marker genes.  
 To determine whether miR-433 regulates mesenchymal lineage commitment, miR-
433 expression will be examined in bone marrow stromal cells differentiated toward the 
osteoblastic, adipogenic, or chondrogenic pathways. BMSCs will be differentiated with an 
osteogenic cocktail containing ascorbic acid and β-glycerophosphate, and early and late 
markers of osteogenesis, miR-433 expression, and staining for alkaline phosphatase and 
Alizarin Red will be examined. C3H/10T1/2 non-targeting and miR-433 decoy cells will be 
differentiated towards osteoblasts using a similar cocktail, with the addition of BMP-2, and 
expression of osteogenic genes will be used as markers for osteogenesis. BMSCs will be 
differentiated towards adipocytes using rosiglitazone and insulin and early, intermediate, 
and late markers of adipogenesis, miR-433 levels and Oil Red O staining will be 
examined. C3H/10T1/2 cells non-targeting and miR-433 decoy cells will be differentiated 
using the same adipogenic cocktail, and expression of adipocyte genes and Oil Red O 
staining will be used to evaluate the effect of miR-433 on adipogenesis. To determine the 
impact of miR-433 on chondrogenesis, BMSCs will be grown in micromass culture, 
differentiated with TGF-β1 and a chondrogenic cocktail. Expression of miR-433 
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expression, chondrocyte marker genes and Alcian blue staining will be examined. 
C3H/10T1/2 non-targeting and miR-433 decoy cells grown in micromass will be 
differentiated with TGF-β1 and BMP-2 to measure the effect on chondrocyte markers. We 
predict miR-433 will inhibit osteoblastic and chondrogenic differentiation. In contrast, we 
predict that miR-433 might increase adipogenesis, since negative regulators of 
osteogenesis are often positive regulators of adipogenesis. 
 
C. Preliminary phenotype of miR-433 decoy mice 
To determine whether the function of miR-433 in osteoblast differentiation in vivo, 
we will develop a transgenic mouse model in which the miR-433 decoy, contained within 
the 3’ UTR of the red fluorescent reporter gene tdTomato, is expressed under the control 
of a 3.6 kb fragment of the rat Col1a1 promoter. Circadian clock and osteoblast mRNA 
expression will be measured in calvaria in mice kept under a 12 hour light/dark cycle, and 
transgenic mice will be compared to wildtype littermates. Additionally, transgenic and 
wildtype controls will be examined by microCT analysis, to determine the potential impact 
of miR-433 on cortical and trabecular bone parameters. We predict miR-433 will be an 
important regulator of the circadian clocks in the calvaria, and that transgenic mice will 
have enhanced bone formation.  
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ABSTRACT 
Serum glucocorticoids play a critical role in synchronizing circadian rhythm in 
peripheral tissues, and multiple mechanisms regulate tissue sensitivity to glucocorticoids. 
In the skeleton, circadian rhythm helps coordinate bone formation and resorption. 
Circadian rhythm is regulated through transcriptional and post-transcriptional feedback 
loops that include microRNAs. How microRNAs regulate circadian rhythm in bone is 
unexplored. We show that in mouse calvaria, miR-433 displays robust circadian rhythm, 
peaking just after dark. In C3H/10T1/2 cells synchronized with a pulse of dexamethasone, 
inhibition of miR-433 using a tough decoy altered the period and amplitude of Per2 gene 
expression, suggesting that miR-433 regulates rhythm. Although miR-433 does not 
directly target the Per2 3’UTR, it does target 2 rhythmically expressed genes in calvaria, 
Igf1 and Hif1α. miR-433 can target the glucocorticoid receptor; however glucocorticoid 
receptor protein abundance was unaffected in miR-433 decoy cells. Rather, miR-433 
inhibition dramatically enhanced glucocorticoid signaling due to increased nuclear 
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receptor translocation, activating glucocorticoid receptor transcriptional targets. Lastly, in 
calvaria of transgenic mice expressing a miR-433 decoy in osteoblastic cells (Col3.6 
promoter), the amplitude of Per2 and Bmal1 mRNA oscillation was increased. miR-433 
was previously shown to target Runx2, and mRNA for Runx2 and its downstream target, 
osteocalcin were also increased in miR-433 decoy mouse calvaria. We hypothesize that 
miR-433 helps maintain circadian rhythm in osteoblasts by regulating sensitivity to 
glucocorticoid receptor signaling.  
INTRODUCTION 
The circadian rhythm is an internal timing mechanism important for orchestrating 
physiological homeostasis, through synchronizing behavioral and physiological patterns. 
This coordinates biological processes critical for overall health, such as tissue repair and 
growth, maintenance of the immune response, and optimization of metabolism. The 
circadian rhythm is driven by a complex interaction between the hypothalamic 
suprachiasmatic nucleus (SCN), also known as the central clock, and the peripheral 
circadian clocks. As the central oscillator, the SCN responds to environmental periodic 
cues such as light, eating patterns, and temperature. In response to these cues, the SCN 
entrains peripheral circadian clocks through stimulation of neural or hormonal signals 
(e.g. glucocorticoids) to enact their effects on target tissues (147).  
In the central oscillator and peripheral tissues, the rhythm is maintained locally by 
clock genes that interact through transcriptional and post-transcriptional feedback loops. 
The main positive regulators are aryl hydrocarbon receptor nuclear translocator-like (Arntl 
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or Bmal1) and circadian locomotor output cycles kaput (Clock), which are negatively 
regulated by the period genes (Per1, Per2, Per3) and the cryptochrome genes (Cry1, 
Cry2), among others (reviewed by (148)). Bmal1 and Clock form a heterodimer and bind 
to E-box elements of target genes, including the Per and Cry genes, to rhythmically induce 
transcription. Per/Cry can negatively feedback to inhibit their own transcription as well as 
the transcription of Bmal1/Clock, ensuring the anti-phasic expression of clock proteins. 
This interaction between the clock proteins determines the oscillatory expression of target 
genes and contributes to the rhythmicity of physiological systems (149).  
Bone is a continuously remodelling tissue, and disturbances in circadian rhythm 
have a negative impact on skeletal health (36,37,150,151). Bone remodelling is the 
coupled cycle of osteoclast-mediated bone resorption followed by osteoblast-mediated 
bone formation. This process is critical for renewal of bone in adults and for mineral 
homeostasis. Imbalance in the bone remodelling process can lead to prevalent diseases, 
such as osteoporosis.  
In osteoblasts, 26% of genes display a diurnal expression pattern, including the 
master osteoblast transcription factor Runt-related transcriptional factor (Runx2), bone 
morphogenetic protein 2 (BMP2), Osteocalcin (Oc, Bglap), Insulin-like Growth Factor 1 
(Igf1), and Hypoxia-inducible factor 1α (Hif1α) (150,151). Evidence suggests that, in 
humans, circadian rhythm coordinates bone remodelling so that it occurs primarily at 
night. For example, bone formation markers such as serum osteocalcin, as well as serum 
markers of type I collagen synthesis, the major protein component of bone matrix, are 
highest in pre-menopausal women at night (37,38). Moreover, serum levels of 
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glucocorticoids, which are known to play an important role in synchronizing peripheral 
clocks, are critical for the diurnal variation in serum osteocalcin (152).  
 microRNAs (miRNAs) are key mediators of post-transcriptional regulation. These 
short (19-25 nucleotide) non-coding RNAs bind specific target mRNAs, resulting in mRNA 
degradation and/or translational suppression. Many miRNAs fine tune the timing and 
tempo of gene expression programs, and these post-transcriptional regulators are an 
important component of circadian clock control. Indeed, miRNAs display circadian 
rhythmicity in many tissues, including the liver, retina and SCN (92,93). miRNAs can 
directly regulate circadian clocks; for example, miR-191 directly targets the 3’ 
untranslated region (UTR) of Bmal1 in the liver (99). Alternatively, miRNAs can indirectly 
control circadian rhythm by targeting downstream regulators, as is the case for miR-122 
targeting of Nocturnin, a key circadian deadenylase. (117). Conversely, clock genes can 
directly regulate miRNA expression; for example, Bmal1/Clock induces expression of 
miR-219, and in vivo miR-219 knockdown results in a lengthened circadian period (111).  
miRNA regulation of circadian rhythm in the skeleton has not been reported. 
However, within the adrenal gland, miR-433 was recently shown to target the 
glucocorticoid receptor (Nr3c1, GR) 3’ UTR (126). Rhythmic secretion of glucocorticoids 
is critical for synchronizing local clocks in peripheral tissues, in part by activating 
transcription of Per genes (76). Moreover, as circulating glucocorticoid levels fluctuate 
diurnally, so does the sensitivity of tissues to glucocorticoids (128). Herein, we 
demonstrate that miR-433 regulates glucocorticoid signaling and impacts the expression 
of the circadian clocks and osteoblastic genes in vitro and in vivo.  
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RESULTS 
miR-433 expression is rhythmic in calvaria  
To determine whether miR-433 might play a role in osteoblast circadian rhythm, 
we first determined if it is under circadian regulation in the skeleton. RNA was isolated 
from calvaria of male mice kept under a 12 hour light/dark cycle, represented as Zeitgeber 
time (ZT). ZT0 is the beginning of light exposure, whereas ZT12 is the beginning of light 
removal. Examining two markers of circadian rhythm Bmal1 and Per2 over two 24 hour 
cycles, these 2 circadian genes displayed the expected anti-phasic pattern of expression 
throughout each 24 hour cycle. For example, Bmal1 mRNA expression was highest at 
ZT1 while Per2 mRNA was low; the nadir for Bmal1 mRNA was just prior to light removal, 
while Per2 mRNA had its peak expression just after dark (Figure 3.1A).  
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Figure 3.1. Rhythmic expression of circadian clock mRNAs, miRNAs and 
osteogenic genes in mouse calvaria and validation of an in vitro model to study 
circadian rhythm. 
C57BL/6J mice were kept under a 12 hour light/dark cycle; calvaria were harvested 
every 4 hours. Two 24 hour cycles are shown. RNA levels were quantified by qRT-
PCR. Zeitgeber time (ZT): ZT0 indicates the beginning of light exposure and ZT12 the 
beginning of light removal. (A) Markers of circadian rhythm, Bmal1 (blue) and Per2 
(red). (B) miR-433 (red), miR-29a (green) and miR-30a (black). (C) Osteogenic genes 
Runx2 (blue), Igf1 (red), and (D) Hif1α (black), and Nr3c1 (glucocorticoid receptor) 
(green). Fold change in each gene is expressed relative to the nadir (n=5). (E) 
Experimental design for synchronizing C3H/10T1/2 cells and primary BMSCs. 
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We analyzed the expression of three microRNAs, miR-433, miR-29a, and miR-
30a, because they were either shown to display rhythmic expression in other tissues or 
predicted via bioinformatics analysis to potentially target the glucocorticoid receptor or 
circadian clock genes (92). miR-433 displayed robust rhythmicity in mouse calvaria 
(Figure 3.1B). The miR-433 expression pattern was anti-phasic in relation to Bmal1 
mRNA, peaking 4 fold after light removal, and decreasing as night progressed. miR-29a 
and miR-30a expression peaked at ZT17, but the amplitude of their rhythm was more 
modest in comparison to miR-433 (Figure 3.1B).  
 
We also examined the mRNA expression of osteogenic genes previously reported 
to display circadian rhythmicity in vivo (36,150). Both Runx2 and Igf1 mRNAs appeared 
to peak early in the day, while Hif1α mRNA displayed a broad peak during each 24 hour 
cycle (Figure 3.1C, D). In contrast, glucocorticoid receptor (Nr3c1) mRNA did not display 
rhythmic expression in calvaria (Figure 3.1D). 
 
Development of an in vitro model to study circadian rhythm 
To better understand the role of miR-433 in circadian rhythm, we used a well-
established protocol in which the multi-potent mouse C3H/10T1/2 cell line and primary 
mouse bone marrow stromal cells (BMSCs) were synchronized with a pulse of the 
synthetic glucocorticoid dexamethasone (140,141). Briefly, C3H/10T1/2 cells and BMSCs 
Expression of Bmal1 (blue) and Per2 (red) mRNA, and miR-433 in synchronized (F, G) 
C3H/10T1/2 cells (n=6) and (H, I) BMSCs (n=3). Data are expressed as fold change in 
gene expression, relative to time 0. * = significantly different from the nadir, p < 0.05. 
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were serum deprived for 24 hours, then treated with a 2 hour pulse of 100 nM 
dexamethasone. The dexamethasone was removed (time 0), replaced with serum free 
medium, and RNA was collected for up to 48 hours (Figure 3.1E). The C3H/10T1/2 cells 
remained synchronized for 48 hours, whereas the BMSCs only remained synchronized 
for ~30 hours. Bmal1 and Per2 mRNA expression displayed rhythmic and anti-phasic 
expression patterns in both C3H/10T1/2 cells and BMSCs, confirming synchronization of 
the cultures (Figure 3.1F, H). However, miR-433 did not display rhythmicity in either cell 
type, suggesting that a systemic factor establishes miR-433 rhythm in vivo (Figure 3.1G, 
I).  
 
miR-433 targets the 3’UTR of Hif1α and Igf1, but not Per2 
To determine whether miR-433 may directly target the circadian clocks, we 
employed a bioinformatic approach using several online databases (miRanda, 
TargetScan, RNAhybrid) to examine complementarity of the miR-433 seed binding region 
to the 3’ UTR of clock mRNAs (153-155). Of the circadian clock genes, only Per2 
contained a potential miR-433 binding site at position 1829 (Figure 3.2A). Runx2, Hif1α 
and Igf1 are rhythmically expressed genes in bone. Whereas Runx2 was previously 
confirmed as a miR-433 target (101), Hif1α and Igf1 had yet to be examined. The Hif1α 
3’ UTR contained 2 potential miR-433 binding sites at positions 352 and 879; the Igf1 3’ 
UTR contained 2 potential sites at 4237 and 6113 (Figure 3.2A). To determine whether 
Per2, Igf1, and Hif1α were miR-433 targets, target gene 3’ UTRs were cloned 
downstream of a constitutively expressed luciferase gene in the reporter plasmid pMIR-
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REPORT. The luciferase constructs containing the target 3’ UTRs were transiently 
cotransfected into  
C3H/10T1/2 cells with a non-targeting 
or miR-433 inhibitor, and luciferase 
activity was quantified. miR-433 
inhibition significantly increased the 
luciferase activity of Hif1α and Igf1 
constructs compared to the non-
targeting control, but it did not affect 
Per2 3’ UTR activity (Figure 3.2B). 
These data suggest that miR-433 
directly targets Igf1 and Hif1α, but not 
Per2. 
 
miR-433 tough decoy suppresses 
miR-433 activity 
To better study the impact of 
miR-433 on circadian rhythm, we 
developed a stably transduced 
C3H/10T1/2 cell line in which the activity of miR-433 could be knocked down in an 
inducible manner. We used a previously described lentiviral knockdown (pSLIK) system 
that allows for tight regulation of transgene expression via a Doxycycline (Dox) inducible 
promoter (144). To achieve knockdown of miR-433 activity, we created a miR-433 tough 
 
Figure 3.2. Examination of miR-433 
targets. 
(A) Potential interaction of miR-433 with 
Hif1α, Igf1, and Per2 3’ UTRs, as predicted 
by miRanda (153). (B) Activity of the Per2, 
Hif1α and Igf1 luciferase-3’ UTR reporter 
constructs transiently transfected into 
C3H/10T1/2 cells, along with a miR-433 or 
non-targeting inhibitor. * = significantly 
different from non-targeting control, p < 0.05. 
n=12.  
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decoy, in which a green fluorescent protein (GFP) reporter carries 2 miR-433 binding sites 
in its 3’ UTR (Table 3.1) (156). The miR-433 tough decoy contains a secondary structure 
that enhances resistance to degradation. When transcribed, the miR-433 tough decoy 
acts as a competitive inhibitor for endogenous miR-433, therefore relieving suppression 
of its targets (Figure 3.4A). As a control, a C3H/10T1/2 cell line was also established 
expressing a Dox-inducible non-targeting tough decoy construct. 
A. 
 
GACGGCGCTAGGATCATCAACACACCGAGGAGCCTAACCATCATGATCAAGTATTCTGG
TCACAGAATACAACACACCGAGGAGCCTAACCATCATGATCAAGATGATCCTAGCGCCG
TCCGA 
B. 
 
GATATCGACGGCGCTAGGATCATCAACTCTACTCTTTCTAGAGCTGAGGTTGTGACAAGT
ATTCTGGTCACAGAATACAACTCTACTCTTTCTAGAGCTGAGGTTGTGACAAGATGATCC
TAGCGCCGTCATCGAT 
Table 3.1. Sequence of miR-433 decoy and non-targeting decoys used in vitro. 
(A) miR-433 tough decoy used in vitro, with miR-433 binding sites underlined 
(GenScript custom synthesis) 
(B) Non-targeting tough decoy used in vitro. It contains C. elegans miR-67 binding 
sites, which are underlined (GenScript custom synthesis) 
 
 
To confirm doxycycline-inducible expression of the transgene, we quantified GFP 
mRNA in the non-targeting and miR-433 decoy cells treated for 24 hours with increasing 
doses of Dox. Dox induced GFP mRNA in both non-targeting and miR-433 decoy cells in 
a dose dependent manner (Figure 3.3B). To confirm the decoy inhibited miR-433 actions, 
we examined luciferase activity of the target 3’UTR constructs that were previously 
studied using the transiently transfected miR-433 inhibitor. In these experiments, the miR-
433 decoy phenocopied the effects observed with transiently transfected miR-433 
inhibitor, with similar increases in luciferase activity with Igf1 and Hif1α 3’ UTR reporter  
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Figure 3.3. miR-433 decoy relieves repression of miR-433 target genes in vitro 
(A) C3H/10T1/2 cells were stably transduced with a Doxycycline (Dox)-inducible 
construct carrying either a non-targeting or miR-433 decoy in the 3’ UTR of the reporter 
gene GFP. Location of the miRNA binding site is denoted by the bold arrows. (B) Dose 
dependent Dox-mediated induction of non-targeting and miR-433 decoy in C3H/10T1/2 
cells. (C) Activity of Per2, Hif1α, and Igf1 luciferase-3’ UTR reporter constructs 
transiently transfected into miR-433 decoy cells cultured in the presence or absence of 
Dox (n=12). Dose dependent Dox-mediated induction of (D) Igf1, (E) Runx2 and (F) 
Hif1α mRNA in miR-433 decoy cells, compared with non-targeting decoy cells (n=4). 
(G) Per2 mRNA was not induced by Dox treatment in either miR-433 or non-targeting 
decoy cells (n=4). * = significantly different from no Dox control, p < 0.05, # = 
significantly different from non-targeting control, p < 0.05.  
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constructs, but no change with Per2 (Figure 3.3C). In miR-433 decoy cells, we also 
examined mRNA levels for a previously defined miR-433 target Runx2 (101), as well as 
Igf1 and Hif1α. Runx2, Igf1 and Hif1α mRNA levels were significantly increased in the 
presence of 1000 ng/ml Dox in the miR-433 decoy cells, but not in the non-targeting decoy 
cells (Figure 3.3D-F). In contrast, Per2 mRNA was unaffected at any dose tested (Figure 
3.3G). Analysis of miR-433 decoy cells at additional time points after Dox treatment also 
failed to demonstrate significant differences in Per2 mRNA (data not shown), confirming 
that Per2 is not a miR-433 target. Overall, these data demonstrate that the miR-433 decoy 
inhibits miR-433 activity. 
 
Disruption of miR-433 activity impacts the rhythmicity of circadian clock  
Although miR-433 did not display a cell-autonomous rhythm in vitro, it is possible 
that this miRNA could still play a role in maintenance or regulation of rhythm. To examine 
this in vitro, non-targeting and miR-433 decoy cells were synchronized with a short pulse 
of dexamethasone, in the presence or absence of Dox. In the synchronized non-targeting 
decoy cells, both Bmal1 and Per2 mRNA displayed 2 peaks within the 48 hour interval. 
Treatment of the non-targeting decoy cells with Dox did not affect the rhythmicity of either 
Bmal1 or Per2 mRNA (Figure 3.4A, D). However, in cells expressing the miR-433 decoy, 
the first peak in Bmal1 mRNA was shifted from 6 hours to 12 hours (Figure 3.4B), and the 
amplitude of the peaks was decreased, an effect particularly evident when the Bmal1 
mRNA levels were expressed as fold change compared with time zero (Figure 3.4C). For 
Per2 mRNA, the effect of miR-433 inhibition was more striking. In miR-433 decoy cells 
treated with Dox, Per2 mRNA levels were significantly higher at time zero, and the phase 
48 
 
of the Per2 rhythm was shifted (Figure 3.4E). Like Bmal1, the amplitude of Per2 mRNA 
peaks was decreased in the presence of the miR-433 decoy (Figure 3.4E, F).  
-  
Figure 3.4. Expression of the miR-433 decoy affects circadian clock mRNA 
rhythmic expression.  
Non-targeting and miR-433 decoy cells were cultured in the absence or presence of 
1000 ng/ml doxycycline, and then synchronized using a 2 hour pulse of 100 nM 
dexamethasone. mRNA was isolated immediately after removal of dexamethasone 
(time 0) and at intervals up to 48 hours thereafter. Data are represented as relative 
expression (left and center columns) or fold change (right column) in non-targeting or 
miR-433 decoy cells. (A-C) Bmal1, (D-F) Per2, Igf1 (G-I), Hif1α (J-L). * = significantly 
different from corresponding time point with no Dox treatment, p < 0.05. n=3. 
 
We also examined expression of osteogenic genes Igf1 and Hif1α in the 
synchronized cultures. Igf1 mRNA was modestly rhythmic in non-targeting decoy cells, 
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exhibiting a single broad peak, and its expression was unaffected by the addition of Dox 
(Fig. 3.4G). Similarly, in miR-433 decoy cells cultured without Dox, Igf1 mRNA also had 
a broad peak at 18-24 hours, and was strongly decreased at 30 hours. In contrast, when 
the miR-433 decoy cells were treated with Dox, Igf1 mRNA levels were significantly higher 
at time zero, and displayed a dramatic decrease between 0 and 6 hours (Fig. 3.4H). The 
effect of the miR-433 inhibition on Igf1 mRNA rhythm was most appreciated when the 
data were expressed as fold change compared with time zero (Fig. 3.4I). In non-targeting 
cells, Hif1α mRNA did not display a clear rhythmic expression pattern, but rather 
increased in expression over time (Fig. 3.4J). However, in miR-433 decoy cells in the 
absence of Dox, Hif1α had 2 peaks of expression at 12 and 30 hours (Fig. 3.4K). In cells 
expressing the miR-433 decoy, Hif1α mRNA was increased at time 0, and the onset of 
Hif1α mRNA rhythm was delayed to 36 hours (Fig. 3.4K, L). Overall, miR-433 levels 
appear necessary for maintenance of rhythmic expression of the circadian clock genes, 
Igf1 and Hif1α mRNA in synchronized cells in vitro.  
 
miR-433 regulates glucocorticoid sensitivity 
Glucocorticoids play a prominent role in synchronizing the peripheral clock genes, 
in part by activating transcription of Per genes (76). Moreover, as circulating 
glucocorticoids levels fluctuate diurnally, so does the sensitivity of tissues to 
glucocorticoids. Since miR-433 was previously shown by others to target the 
glucocorticoid receptor 3’ UTR (126), and because our cell cultures were synchronized 
using dexamethasone, we hypothesized that miR-433 could help maintain circadian 
rhythm in cells of the osteoblastic lineage through regulation of glucocorticoid signaling. 
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Dusp1 and Per2 are both direct transcriptional targets of the glucocorticoid 
receptor, and we used their mRNA levels as markers of glucocorticoid signaling (76,146). 
In C3H/10T1/2 cells, dexamethasone induced Dusp1 mRNA at 1-3 hours, whereas the 
increase in Per2 was more transient, peaking at 2 hours (Figure 3.5A, B). To determine 
whether miR-433 regulated the sensitivity of cells to glucocorticoids, we examined Dusp1 
and Per2 mRNA in miR-433 decoy cells treated for 2 hours with vehicle or 
dexamethasone, in the absence or presence of Dox. In the absence of miR-433 decoy, 
dexamethasone caused a modest increase in Per2 mRNA, independent of the dose used 
(Figure 3.5C). In contrast, expression of the miR-433 decoy augmented the induction of 
Per2 mRNA, and caused a dose-responsive increase. In the absence of miR-433 decoy, 
10 or 100 nM dexamethasone increased Dusp1 mRNA ~6 fold (Figure 3.5D). Expression 
of the miR-433 decoy further enhanced Dusp1 mRNA at both 10 nM and 100 nM 
dexamethasone (Figure 3.5D). Since inhibition of miR-433 activity allowed the cells to 
become responsive to higher levels of glucocorticoids, it is possible that miR-433 
functions to limit exposure of cells to excessive glucocorticoid signaling.  
 
To determine how miR-433 might regulate sensitivity to glucocorticoid signaling, 
we first examined the impact of the miR-433 decoy on glucocorticoid receptor mRNA 
(Nr3c1) and protein levels. To mimic the conditions of the circadian synchronization  
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experiments, we performed these studies in cells cultured for 24 hours in the presence or 
absence of Dox, then treated with 100 nM dexamethasone for 2 hours. In non-targeting 
 
Figure 3.5. miR-433 dampens sensitivity to glucocorticoid signaling. 
(A) Per2 and (B) Dusp1 mRNA in serum-deprived C3H/10T1/2 cells treated with vehicle 
or 100 nM dexamethasone for up to 3 hours. (C) Per2 and (D) Dusp1 mRNA levels in 
miR-433 decoy cells that were serum-deprived in the presence or absence of Dox, and 
then treated with increasing doses of dexamethasone for 2 hours. Per2 mRNA levels 
in (E) non-targeting decoy or (F) miR-433 decoy cells that were serum-deprived in the 
presence or absence of Dox, and then treated with vehicle or 100 nM dexamethasone 
for up to 4 hours (n=8). Dusp1 mRNA levels in (G) non-targeting decoy or (H) miR-433 
decoy cells that were serum-deprived in the presence or absence of Dox, and then 
treated with vehicle or 100 nM dexamethasone for up to 4 hours (n=8). * = significantly 
different from corresponding no Dox control, p < 0.05; # = significantly different from 
corresponding vehicle treated control, p < 0.05.  
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decoy cells, culture in the presence or absence of Dox did not affect mRNA or protein 
levels of Nr3c1 (Figure 3.6A, D). In contrast, miR-433 decoy cells treated with Dox 
displayed a 3 fold induction of Nr3c1 mRNA (Figure 3.6A). However, significant 
differences in total glucocorticoid receptor (GR) protein levels were not observed at any 
time point measured (Figure 3.6D). It is possible that inhibition of miR-433 alters GR 
mRNA translation efficiency, perhaps by indirectly modifying the complement of miRNAs 
or RNA binding proteins interacting with the transcript. GR protein stability could also be 
affected, since GR is subject to ubiquitin-mediated degradation. Overall, these data 
suggest that an increase in total glucocorticoid receptor levels was not responsible for the 
increased sensitivity to dexamethasone.  
 
Alternative forms of the mouse glucocorticoid receptor, GRα or GRβ, are 
generated by alternative splicing (157). It was previously reported that GRα acts as a 
transcriptional activator of glucocorticoid signaling, whereas GRβ can act as a dominant 
negative inhibitor of GRα (157-159). Since commercially available antibodies for the 
mouse glucocorticoid receptor do not discriminate between GRα and GRβ isoforms, we 
relied on isoform-specific qRT-PCR to determine whether miR-433 inhibition might cause 
differences in the expression of GRα versus GRβ mRNA. miR-433 decoy cells were 
cultured in the absence or presence of Dox for 24 hours, and then treated with or without 
dexamethasone for 2 hours. GRα mRNA was increased in miR-433 decoy cells cultured 
in Dox, and treatment with dexamethasone did not alter GRα mRNA levels (Figure 3.6B). 
GRβ mRNA levels were also increased in Dox treated cells, however dexamethasone 
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decreased GRβ mRNA levels by about 50%, whether the miR-433 decoy was expressed 
or not (Figure 3.6C). These data suggest that although  
 
Figure 3.6. miR-433 regulates glucocorticoid receptor mRNA and subcellular 
localization. 
Non-targeting and miR-433 decoy cells were serum-deprived for 24 hours in the 
presence or absence of Dox, and then treated with 100 nM dexamethasone for 2 hours. 
(A) Total glucocorticoid receptor mRNA, and glucocorticoid receptor mRNA isoforms, 
(B) GRα and (C) GRβ were quantified (n=8). (D) miR-433 decoy cells were serum-
deprived in the presence or absence of Dox for 24 hours, then treated with 100 nM 
dexamethasone for 2, 3, 6, or 24 hours. Total glucocorticoid receptor protein levels 
were determined by Western blot (representative blot, 2 hour time point, above) and 
were quantified (below) (n=4). miR-433 decoy cells were serum-deprived for 24 hours 
in the presence or absence of Dox, and then treated for 2 hours with 100 nM 
dexamethasone. Glucocorticoid receptor subcellular localization was determined by 
Western blot (representative blot, above) and were quantified (below): (E) cytoplasmic 
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and (F) nuclear extracts (n=10). miR-433 decoy cells were serum-deprived for 24 hours 
in the absence or presence of Dox, and HDAC6 (G) mRNA and (H) protein were 
quantified (n=7). * = significantly different from corresponding no Dox control, p < 0.05; 
# = significantly different from corresponding vehicle treated control, p < 0.05. 
 
dexamethasone affects the mRNA ratio of GRα to GRβ, inhibition of miR-433 activity does 
not impact this ratio. 
 
Since the miR-433 decoy increased glucocorticoid signaling in the absence of 
significant increases in GR protein levels or changes in receptor isoform mRNA, we next 
examined whether miR-433 levels might affect the nuclear versus cytosolic localization 
of the GR. In the absence of ligand, GR is localized primarily in the cytoplasm, in a 
complex that includes heat shock protein 90, immunophilins and non-receptor tyrosine 
kinases (160). Upon ligand binding to the GR, this complex is dissociated and GR dimers 
translocate to the nucleus to elicit transcriptional regulation of target genes. We 
hypothesized that miR-433 inhibition might increase nuclear GR with glucocorticoid 
stimulation. To test this, miR-433 decoy cells were cultured in the presence or absence 
of Dox for 24 hours, then treated with or without dexamethasone for 2 hours. The levels 
of GR in nuclear and cytoplasmic compartments were evaluated by Western blotting. In 
the absence of dexamethasone, the majority of glucocorticoid receptor was found in the 
cytoplasm, and expression of the miR-433 decoy did not significantly alter its abundance. 
As expected, when cells were treated with dexamethasone, the abundance of GR in the 
cytoplasm was dramatically decreased; this decrease was also not significantly affected 
by expression of the miR-433 decoy (Figure 3.6E). Examining the nuclear compartment, 
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in the absence of dexamethasone stimulation, GR levels were similar in cells with or 
without the miR-433 decoy. However, in cells treated with dexamethasone there was an 
increase in nuclear GR levels, which was significantly enhanced by expression of the 
miR-433 decoy (Figure 3.6F). The enhanced translocation and possibly maintenance of 
the glucocorticoid receptor to the nucleus upon ligand binding provides a potential 
mechanism for the enhanced responsiveness of miR-433 decoy cells to dexamethasone. 
 
Heat shock protein 90 (HSP90) plays an important chaperone function for GR in 
both the cytoplasm and nucleus. Hyperacetylation of HSP90 results in loss of its GR 
chaperone activity, causing defects in GR ligand binding, nuclear translocation and 
transcriptional activation (135,161). Histone deacetylase 6 (HDAC6) can deacetylate 
HSP90, and in humans, miR-433 has been shown to target HDAC6 (135). Should the 
miR-433 decoy increase expression of HDAC6, it could represent a potential mechanism 
for increasing GR nuclear localization. In miR-433 decoy cells cultured in the presence of 
Dox, HDAC6 mRNA expression and protein levels were significantly increased (Figure 
3.6G, H), indicating that miR-433 targets HDAC6 in mice as well as humans. miR-433 
effects on HDAC6 could contribute to its regulation of glucocorticoid sensitivity. 
 
Glucocorticoids down regulate miR-433 
Since microRNAs often participate in feedback loops, we determined whether 
glucocorticoids might regulate the expression of miR-433. In serum deprived C3H/10T1/2 
cells treated with 100 nM dexamethasone for up to 24 hours, we found a modest (20-
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25%) but significant reduction of miR-433 only at the 24 hour time point (Figure 3.7A). 
Serum deprived confluent cultures of primary BMSCs displayed a similar decrease in 
miR-433 expression with dexamethasone treatment (Figure 3.7B). This delay in response 
suggests dexamethasone indirectly regulates miR-433 expression, or it could reflect the 
generally long half-life of many miRNAs.  
 
 
Figure 3.7. Dexamethasone decreases miR-433 expression. 
miR-433 levels in serum-deprived (A) C3H/10T1/2 cells or (B) mouse bone marrow 
stromal cells treated with vehicle or 100 nM dexamethasone for up to 24 hours. # = 
significantly different from vehicle control, p < 0.05. n=4. 
 
miR-433 regulates circadian clocks and osteoblastic genes in vivo 
Our in vitro studies indicated that miR-433 activity dampens glucocorticoid 
signaling and is important for maintaining rhythmic gene expression in osteoblastic cells. 
To determine whether miR-433 plays a similar role in the regulation of the circadian clocks 
in vivo, we developed a transgenic mouse model in which the miR-433 decoy, contained 
within the 3’ UTR of the red fluorescent reporter gene tdTomato, was expressed under 
the control of a 3.6 kb fragment of the rat Col1a1 promoter (miR-433 decoyCol1a1 mice) 
(Figure 3.8A, B). Previous studies document that transgenes under the control of this 
promoter are expressed most abundantly in osteoblastic cells, with lesser expression in 
other type I collagen containing tissues (162,163). Fluorescence microscopy of calvarial 
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sections from miR-433 decoyCol1a1 mice demonstrated that signal for tdTomato was 
localized to osteocytes embedded in the bone matrix, and cells on the periosteal and 
endosteal surfaces, where new bone is formed (Figure 3.9A).  
 
A. 
GACGGCGCTAGGATCATCAACACACCGAGGAGCCTAACCATCATGATCAAGTATTCTGG
TCACAGAATACAACACACCGAGGAGCCTAACCATCATGATCAAGATGATCCTAGCGCCG
TCCaggttgttccaatgccaatctgtaaatacgagattcttaacgggttcaattcgcaactattggacaacaacacaaatggacc
GACGGCGCTAGGATCATCAACACACCGAGGAGCCTAACCATCATGATCAAGTATTCTGG
TCACAGAATACAACACACCGAGGAGCCTAACCATCATGATCAAGATGATCCTAGCGCCG
TCGGCCGGCCGTCGACCTGCAGTtttgaagaagagatccgctccagtaatggagaatattcttgatgtGACGG
CGCTAGGATCATCAACACACCGAGGAGCCTAACCATCATGATCAAGTATTCTGGTCACA
GAATACAACACACCGAGGAGCCTAACCATCATGATCAAGATGATCCTAGCGCCGTCCGA 
 
B.  
 
Figure 3.8. Sequence of miR-433 decoy used in vivo. 
(A) Sequence of miR-433 decoy used for transgenic mouse: Three miR-433 tough 
decoys were assembled. DNA from the coding region of the C. elegans Cut3 gene was 
used as spacer between the repeats of miR-433 decoy, and is denoted by lower case 
letters. The miR-433 binding sites are underlined. The fragment was custom 
synthesized by GenScript.  
(B) Schematic of Col3.6/1.6_tdTomato_miR-433 decoy transgene cassette. A 3.6 kb 
fragment of the rat Col1a1 gene, plus the first intron, was used to drive expression of 
the reporter gene tdTomato and a 3’ UTR containing 3 copies of a miR-433 tough decoy 
(miR-433 binding sites are denoted by black arrows), a Woodchuck Hepatitis Virus 
Posttranscriptional Regulatory Element (WPRE), and bovine growth hormone 
polyadenylation signal (polyA). 
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To determine the impact of miR-433 on circadian rhythm, RNA was isolated from 
calvaria of 8 week old male miR-433 decoyCol1a1 mice and matched litter mate controls 
euthanized every 6 hours over an 18 hour period. Bmal1 and Per2 mRNA expression  
 
Figure 3.9. miR-433 regulation of circadian clocks and osteoblast genes in vivo. 
Calvaria were isolated from male transgenic mice expressing the miR-433 decoy under 
the control of a Col1a1 promoter (miR-433 decoyCol1a1 mice) and wild type litter mate 
controls. (A) Example of TD Tomato transgene and Dapi fluorescence in a calvarium 
from a 4 week old male miR-433 decoyCol1a1 mouse at ZT13. mRNA levels from calvaria 
of 8 week old mice for (B) Bmal1 and (C) Per2 at ZT 1, 7, 13, and 19. (D) Runx2 and 
Dusp1 and (E) osteocalcin (Oc) and Igf1 mRNA were quantified in calvaria at ZT13. 
Pooled data from 2 miR-433 decoyCol1a1 lines having a similar level of transgene 
expression. n=7 for WT; n=8 for miR-433 decoyCol1a1. * = significantly different WT 
littermates, p < 0.05.  
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showed rhythmic and anti-phasic expression in both wildtype and miR-433 
decoyCol1a1 mice (Figure 3.9B, C). However, the amplitude of Bmal1 mRNA rhythm in 
miR-433 decoyCol1a1 mice was significantly increased compared to littermate controls 
(Figure 3.9B). The amplitude of Per2 mRNA rhythm was also significantly increased in 
miR-433 decoyCol1a1 mice (Figure 3.9C). Thus, miR-433 dampens the rhythm of circadian 
clock genes in vivo, supporting its role in the regulating circadian rhythm. 
 
miR-433 can directly target Runx2 and Igf1, suggesting that it may negatively 
regulate osteoblastogenesis (101). Indeed, calvaria from miR-433 decoyCol1a1 mice had 
1.5 fold higher levels of Runx2 mRNA, as well as elevated mRNA for the Runx2 target 
gene, osteocalcin. In contrast, Igf1 mRNA was similar in wild type and miR-433 
decoyCol1a1 mice (Figure 3.9). Overall, inhibition of miR-433 activity increased the 
expression of glucocorticoid-responsive genes and increased expression of a subset of 
osteoblast marker genes in vivo, supporting in vitro observations.  
 
DISCUSSION 
 
The circadian clocks are crucial regulators of organismal physiology and behavior, 
operating through a series of positive and negative feedback loops, the regulation of 
which includes microRNAs. In this study, we demonstrate that miR-433 displays a robust 
rhythmic expression in the calvaria and that miR-433 is important in maintaining the 
rhythmic expression of the circadian clocks in vitro and in vivo. miR-433 serves to limit 
the responsiveness of mesenchymal cells to glucocorticoids, which could contribute to its 
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regulation of circadian rhythm (Figure 3.10). In addition, we identified 2 novel targets of 
miR-433, Igf1 and Hif1α, both of which display rhythmicity in vivo and play an important 
role in osteogenesis. Altogether, we showed that miR-433 can modify responsiveness of 
cells to glucocorticoids, providing a potential mechanism contributing to its ability to 
regulate rhythmic gene expression in bone, and possibly other tissues.   
 
Although microRNAs were shown to be important regulators of circadian rhythm in 
non-skeletal tissues (93,99,111), to our knowledge, this is the first study examining the 
role of miRNAs in circadian rhythm in bone. In our study, miR-433 displayed a sizeable 
rhythmicity in the calvaria, its rhythm had a larger amplitude compared with miR-29a and 
miR-30a, two microRNAs previously shown to display significant rhythmicity in the liver 
(92). It is likely that other miRNAs display circadian rhythm in the calvaria, and this 
remains to be examined.  
 
Figure 3.10. Working model of miR-433 regulation of glucocorticoid-induced 
synchronization of circadian rhythm.  
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miRNAs can regulate circadian rhythm through direct targeting of the circadian 
clocks, by regulation of entrainment, or by reducing target mRNAs’ oscillation amplitude 
or frequency (102). Several miRNAs have been found to impact circadian rhythms in the 
liver, with miR-122 being the most studied. The miR-122 locus in under the direct 
regulation of REV-ERBα, an important circadian protein that functions by recruiting 
histone deacetylases (HDACs), repressing gene expression (115). Systemic 
administration of miR-122 antisense oligonucleotides caused substantial alterations in 
amplitude, magnitude, and phase of several rhythmic mRNAs in liver, with corresponding 
changes in expression of genes involved in cholesterol and lipid metabolism (115). 
Whereas previous studies examined the direct regulation of miRNAs on the circadian 
clocks, our study suggests that miR-433 regulation of glucocorticoid signaling in 
peripheral tissues could impact the rhythmic expression of the circadian clocks in vivo, 
i.e. synchrony. 
 
Glucocorticoids, among other hormones, are important entrainment signals that 
synchronize circadian rhythms in the kidney, liver, heart, and other tissues (70). High 
levels of glucocorticoids can disrupt circadian rhythm (78). In humans, serum levels of 
glucocorticoids cycle, with their peak in the early morning, just before waking, and their 
lowest levels in the evening (73). The circadian clocks can be directly regulated by 
glucocorticoid signaling, as the glucocorticoid receptor transcriptionally activates 
expression of Per1 through a GRE in its promoter, and Per2 through a GRE in the first 
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intron (74-76). Indeed, oscillating levels of circulating glucocorticoids correspond to Per1 
levels in peripheral tissues (77).  
 
Glucocorticoid receptor-induced transcriptional activity can also be directly 
suppressed by Clock, which assists with acetylating the GR hinge domain (68,128). This 
acetylation attenuates the binding of the GR to GREs, limiting its actions. In peripheral 
tissues, the Bmal1/Clock-mediated counter regulation of glucocorticoid signaling provides 
a mechanism to prevent over exposure of target tissues to glucocorticoids at times when 
serum levels of glucocorticoid are at their peak (147). Similarly, we demonstrate that miR-
433 activity blunts glucocorticoid signaling. In mice, miR-433 levels peak just after dark 
(Figure 1), and serum glucocorticoids peak just before dark (164). In calvaria of miR-433 
decoyCol1a1 mice, we observed increased mRNA for the glucocorticoid receptor target 
genes Per2 and Dusp1, further supporting the concept that miR-433 serves as an 
additional mechanism to limit exposure of osteoblastic cells to glucocorticoids in vivo.  
 
In humans, miR-433 has been shown to target HDAC6 (135), suggesting that miR-
433 levels could regulate the acetylation status of HDAC6 targets. Indeed, HDAC6 can 
deacetylate Hsp90, which plays an important chaperone function for GR in both the 
cytoplasm and nucleus. Hyperacetylation of HSP90 results in loss of its GR chaperone 
activity, causing defects in ligand binding, nuclear translocation and transcriptional 
activation of GR target genes (135,161). Our results indicate that miR-433 can regulate 
the sensitivity of cells to glucocorticoids through decreasing translocation of the GR to the 
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nucleus. It is possible that the ability of miR-433 to target HDAC6 helps to control HSP90 
acetylation and chaperone function, fine-tuning glucocorticoid responsiveness.  
 
The role of glucocorticoid signaling in bone is complex. Normal, endogenous 
glucocorticoids are critical for skeletal health (reviewed by (79)). Glucocorticoids can 
enhance the expression of osteoblast differentiation markers such as alkaline 
phosphatase, osteocalcin and bone sialoprotein in vitro (reviewed by (80)). In contrast, 
excessive exposure of the skeleton to glucocorticoids leads to the development of 
osteoporosis, which is frequently seen in patients treated long term with glucocorticoids 
for autoimmune disorders, inflammatory disease or malignancy. Glucocorticoid excess 
causes bone loss due to decreased osteoblast activity, reduced osteoblast number, 
increased osteocyte apoptosis, and disruption of extracellular matrix production 
(reviewed by (81)). In our in vivo model, calvaria from mice expressing the miR-433 decoy 
in osteoblastic cells had increased mRNA for Runx2 and its downstream target, 
osteocalcin. This was not unexpected, since miR-433 was previously shown to target 
Runx2 (101). That Igf1 was not similarly increased suggests other mechanisms, 
transcriptional or post-transcriptional, predominate in the regulation of this gene in vivo. 
We are in the process of fully characterizing the skeletal phenotype of miR-433 
decoyCol1a1 mice, to better understand the function of miR-433 in bone. 
 
We identified 2 new miR-433 targets, Hif1α and Igf1, which have been shown to 
be to be important factors in bone formation and homeostasis (165-168). Igf1 enhances 
osteoblast differentiation and induces osteoblast proliferation (167). Hif1α is important in 
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coupling angiogenic and osteogenic activity, to promote bone formation (166,168). In 
calvaria, miR-433 levels are highest when mRNA of its targets, Runx2 and Igf1, are the 
lowest. In contrast, the peak of miR-433 coincides with a broad peak in Hif1α mRNA. It is 
possible that miR-433 serves to fine tune expression of this regulator. 
 
Transcription of the miR-433 locus has been shown to be induced by orphan 
receptor estrogen related receptor γ (ERRγ), a negative regulator of osteogenesis, 
whereas its transcription can be repressed by small heterodimer partner (SHP) which 
promotes osteoblast differentiation (101,169,170). Although estrogen related receptors 
have been linked to energy homeostasis and can display circadian regulation, it is not 
known whether these mechanisms are active in calvaria (171,172). Disruption of normal 
circadian rhythm resulting in changes of clock amplitude, period length, or frequency lead 
to alterations in chromatin modification, gene regulation, cellular metabolism, and immune 
responses (42). Consequently, chronic desynchrony is associated with the development 
and progression of cardiovascular disease, cancer, mental illnesses, and severe 
metabolic disorders (reviewed by (45)).   
 
Overall, we found miR-433 displays rhythmicity in calvaria, regulates cell sensitivity 
to glucocorticoids, and helps maintain rhythmic gene expression. Since miR-433 levels in 
bone peak when circulating glucocorticoid levels are high, it likely plays a role in balancing 
the glucocorticoid response. We speculate that miR-433 can modify responsiveness of 
peripheral tissues to variations in circulating glucocorticoids and alter bone metabolism. 
miR-433 also targets HDAC6, providing a mechanism for modulating the acetylation 
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status of multiple HDAC6 targets. These findings provide an added dimension to our 
understanding of the mechanisms regulating glucocorticoid responsiveness, circadian 
rhythm, and their potential impact on the skeleton, and possibly other tissues.  
 
EXPERIMENTAL PROCEDURES 
Mice 
C57BL/6 male mice were kept under a 12 hour light/dark cycle, and provided with 
food and water ad libitum. Eight week old male mice were euthanized every 4 hours and 
calvaria were collected. We created mice expressing a transgene in which a 3.6 kb 
fragment of the rat col1A1 promoter, plus 1.6 kb of the first intron drive expression of the 
tdTomato reporter gene carrying a miR-433 tough decoy (TuD) in its 3’ UTR (custom 
synthesis, GenScript, Piscataway, NJ) (156,162). Mice were generated in a C57BL/6 
background by pronuclear injection of the transgene cassette at the UConn Health Gene 
Targeting and Transgenic Facility. The miR-433 decoy serves as a competitive inhibitor 
of miR-433 activity, relieving the suppression of endogenous miR-433 targets. The 
sequence of the miR-433 TuD and diagram of the transgene cassette is provided in Figure 
3.9. Eight week old male mice were euthanized at ZT13 and calvaria were collected. 
All animal protocols were reviewed and approved by the UConn Health Institutional 
Animal Care and Use Committee (IACUC). 
 
Cell culture and synchronization 
C3H/10T1/2, Clone 8, a multipotent mouse mesenchymal cell line, was obtained 
from the American Type Culture Collection (ATCC® CCL-226™) and cultured in DMEM 
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(Gibco Life Technologies, Carlsbad, CA) supplemented with 10% heat-inactivated Fetal 
Bovine Serum (FBS, Lonza, Basel, Switzerland). Primary bone marrow stromal cells 
(BMSCs) were flushed from the long bones of 6-8 week old male C57BL/6 mice and 
maintained in DMEM supplemented with 10% FBS. Cells were synchronized by 24 hours 
of serum deprivation, followed by treatment for 2 hours with 100 nM dexamethasone 
(Sigma-Aldrich, St. Louis, MO). The dexamethasone was then replaced with serum-free 
medium for the remainder of the experiment (140). Amplitude was determined by 
calculating the difference between a peak and the mean value of the wave. 
 
Quantitative real time PCR 
 Total RNA from calvaria samples was extracted using the miRNeasy Mini Kit 
(Qiagen, Valencia, CA). Calvaria were homogenized in Qiazol. RNA was isolated from 
cell cultures using TRIzol Reagent (Life Technologies). RNA samples were DNased using 
RQ1 DNase (Promega, Madison, WI). DNased RNA was reverse-transcribed using 
Moloney murine leukemia virus-reverse transcriptase (Invitrogen, Carlsbad, CA). Gene 
expression was quantified by qPCR with iQ SYBR Green Supermix (Bio-Rad) and 
normalized to 18S rRNA. Primer sets are shown in Table 3.2. microRNA expression levels 
were analyzed using the TaqMan MicroRNA Assay (Life Technologies). RNA was reverse 
transcribed with gene-specific primers to generate cDNA. microRNA expression was 
detected by qPCR and normalized to snoRNA 202. RNA experiments were performed at 
least twice and each experiment contained at least 3 biological replicates. Each sample 
was assayed in duplicate. 
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Table 3.2:  Primer sequences used for qPCR analysis.   
Gene (mouse) Sequence 
18S (sense) 
18S (antisense) 
5’-GCGTGTGCCTACCCTACGCC -3’ 
5’-ACGCAAGCTTATGGCCCGCA-3’ 
Bmal1 (sense) 
Bmal1 (antisense) 
5’-AACCTTCCCGCAGCTAACAG -3’ 
5’-AGTCCTCTTTGGGCCACCTT -3’ 
Per2 (sense) 
Per2 (antisense) 
5’-AGAACGCGGATATGTTTGCTG-3’ 
5’-ATCTAAGCCGCTGCACACACT-3’ 
Hif1α (sense) 
Hif1α (antisense) 
5′-ACCTTCATCGGAAACTCCAAAG -3′  
5′-ACTGTTAGGCTCAGGTGAACT-3′ 
Nr3c1 (sense) 
Nr3c1 (antisense) 
5′-GTGAGTTCTCCTCCGTCCAG -3′  
5′-TGCAATCATTTCTTCCAGCA-3′ 
Runx2 (sense) 
Runx2 (antisense) 
5′-CCTCTGGCCTTCCTCTCTCAGT -3′  
5′-GCCACTCTGGCTTTGGGAAGAG -3′ 
Igf1(sense) 
Igf1 (antisense) 
5′-CACACTGACATGCCCAAGAC -3′  
5′-GGGAGGCTCCTCCTACATTC -3′ 
GFP (sense) 
GFP (antisense) 
5′-GTGAGCAAGGGCGAGGAGCTGTTC -3′  
5′-GTAGGTCAGGGTGGTCACGAGGG -3′ 
GRα (sense) 
GRα (antisense) 
5′-AAAGAGCTAGGAAAAGCCCATTGTC-3′  
5′-TCAGCTAACATCTCTGGGAATTCA -3′ 
GRβ (sense) 
GRβ (antisense) 
5′-AAAGAGCTAGGAAAAGCCCATTGTC-3′  
5′-CTGTCTTTGGGCTTTTGAGATAGG -3′ 
Dusp1 (sense) 
Dusp1 (antisense) 
5′-CAGCTGCTGCAGTTTGAGTC -3′  
5′-GGGATGGAAACAGGGAAGTT -3′ 
 
Luciferase assay 
Gene-specific PCR primers were used to amplify from genomic DNA template the 
3’ UTR for Igf1 (mouse, base pairs 1-6217), Hif1α (human, base pairs 2612-3906), and 
Per2 (human, base pairs 866-2041). These fragments were subcloned downstream of a 
Cytomegalovirus (CMV) promoter-driven Luciferase reporter (pMIR-REPORT vector, 
Ambion, Carlsbad, CA). Constructs were verified by sequencing. 
 
C3H/10T11/2 cells were plated a 25,000 cells/cm2. BioT transfection reagent 
(1.5ul:1μg DNA; Bioland Scientific, Paramount, CA) was used to co-transfect luciferase 
constructs containing the 3’ UTR of target mRNA, a constitutively active β-galactosidase 
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construct (control for transfection efficiency), and miRNA hairpin inhibitors 
(Dharmacon/Thermo Fisher Scientific, Waltham, MA). 80 nM of anti-miR-433 or a 
negative control (non-targeting) miRNA inhibitors were used. Cell lysates were analyzed 
for luciferase activity using the Luciferase Assay System (Promega) and normalized to β-
Galactosidase using Galacton® (Life Technologies). Each luciferase experiment was 
performed at least 3 times, and each experiment contained 6 biological replicates. More 
than one preparation of each DNA construct was tested. 
 
Establishment of a stable inducible miR-433 knockdown model 
To achieve knockdown of miR-433 activity, C3H/10T11/2 cells were transduced 
using lentiviral constructs containing a miR-433 tough decoy (custom synthesis, 
GenScript) driven by a doxycycline (Dox)-inducible promoter. The miR-433 decoy 
contains complementary sites that will bind endogenous miR-433 (Table 3.1). The miR-
433 decoy was subcloned into the single lentivector for inducible knockdown (pSLIK) 
system and confirmed by sequencing (144) (Addgene, Cambridge, MA). Doxycycline 
treatment stimulates the decoy. As a control, we developed a non-targeting tough decoy 
containing C. elegans miR-67 binding sites (custom synthesis, GenScript), which is not 
predicted to interact with mammalian miRNAs (Table 3.1). Cells stably transduced with 
the pSLIK-miR-433 decoy or non-targeting decoy were selected for hygromycin 
resistance.  
 
Western blot  
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C3H/10T1/2 cells were plated at 200,000 cells/cm2 and treated with Doxycyline for 
24 hours in serum-free medium, to induce expression of the decoy. Cells were lysed with 
RIPA buffer containing Halt™ protease inhibitors (Thermo Fisher Scientific). A BCA assay 
(Thermo Fisher Scientific) was performed to quantify protein, and 20 µg protein was 
subjected to electrophoresis on a 10% SDS polyacrylamide gel. Proteins were transferred 
to a PVDF membrane (Millipore, Billerica, MA). Rabbit anti-mouse glucocorticoid receptor 
primary antibody (1:1000 Cell Signaling, Danvers, MA, Cat #D6H2L), rabbit anti-β-actin 
antibody (1:2000, Cell Signaling #13E5), and goat anti-rabbit horseradish peroxidase 
conjugated antibody (1:10000, Sigma Aldrich A0545) were used.  
 
To analyze nuclear versus cytosolic localization of the glucocorticoid receptor, 
C3H/10T1/2 cells were serum deprived for 24 hours, in the presence or absence of 
doxycycline, then treated with or without 100 nM dexamethasone for 2 hours. Cells were 
trypsinized and pelleted. Pellets were suspended in a cytosolic extraction buffer (10 mM 
Hepes, 60 mM KCl, 1 mM EDTA, 0.075% Igepal 40, 1 mM DTT, and 1 mM PMSF). The 
lysate was pelleted and the supernatant was collected as the cytosolic fraction. Pellets 
were resuspended in nuclear extraction buffer (20 mM Tris-Cl, 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1 mM PMSF, and 25% Glycerol), and then pelleted; the 
supernatant was collected as the nuclear fraction. Half of each lysate was subjected to 
electrophoresis on a 10% SDS polyacrylamide gel, transferred to PVDF membrane, and 
the same antibody dilutions as noted above were used for the glucocorticoid receptor and 
β-actin. For the nuclear fraction, rabbit anti-mouse PCNA was used to control for loading 
(1:2000 Cell Signaling Cat #13110P). Chemiluminescent signal was achieved using 
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SuperSignal West Pico Kit (Thermo Fisher Scientific) and captured using the Bio-Rad 
ChemiDoc XRS+ Imaging system. Densitometry of protein bands were performed using 
Image J analysis (173). Expression of the glucocorticoid receptor was normalized to either 
β-actin or PCNA.  
 
Cryohistology and microscopy imaging 
Calvaria from 4 week old male mice were fixed (4% paraformaldehyde), decalcified 
(14% EDTA-acid, 0.9% ammonium hydroxide), and washed in a 30% sucrose PBS 
solution at 4º C. Samples were embedded in O.C.T. compound (VWR, Radnor, PA). 7 
µm sections were collected with a Cryofilm type II tape transfer system (Section Lab Co. 
Ltd. Japan). Sections were mounted for imaging (50% glycerol buffered with PBS 
containing 0.2 mg/ml DAPI, Thermo Scientific Fisher), imaged with a Zeiss Observer Z.1 
microscope, and captured using an Axiocam MRc digital camera and Axiovision software 
(Zeiss). 
 
Statistics 
All data are represented as a mean ± SEM, and are either a representative of 2 
experiments (n=3-4 biological replicates/experiment) or pooled data from several 
experiments (n>4 biological replicates). Statistical significance was determined using two 
tailed ANOVA with Bonferroni post-hoc test or a Student’s t test as appropriate 
(KaleidaGraph, Synergy Software, Reading, PA).  
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Abstract 
Osteoblasts, chondrocytes, and adipocytes arise from a common progenitor, and 
microRNAs (miRNAs) are key post-transcriptional regulators of lineage commitment and 
differentiation. Transforming growth factor β (TGF-β) is critical for both osteoblastic and 
chondrogenic commitment; bioinformatic analyses suggest that miR-433 could target key 
components of the TGF-β signaling pathway. Therefore, we examined the function of 
miR-433 in osteoblast and chondrocyte differentiation using a mesenchymal cell line 
where miR-433 activity was inhibited using a tough decoy. Inhibiting miR-433 amplified 
TGF-β signaling, determined by SBE4 luciferase reporter. Moreover, inhibition of miR-
433 increased pSMAD2 and SMAD2 in TGF-β treated mesenchymal cells. 3’UTR 
luciferase assays validated SMAD2 and TGFBR1 as novel miR-433 targets. Examining 
miR-433 during lineage commitment in primary cultures of mouse bone marrow stromal 
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cells (BMSCs), we found that osteogenic differentiation profoundly decreased miR-433 
expression. In contrast, miR-433 levels were dramatically increased during the 
chondrogenic differentiation of mouse BMSCs or human induced pluripotent stem cell 
(iPSC) derived mesenchymal-like progenitors. In multipotent C3H/10T1/2 cells 
expressing the miR-433 tough decoy, inhibition of miR-433 enhanced BMP2-induced 
osteogenic differentiation, and promoted mineralized matrix deposition. In miR-433 decoy 
cells induced toward the chondrogenic lineage, miR-433 inhibition promoted expression 
of chondrogenic mRNAs, Sox9, Col2a1, and ColXa1. Overall, miR-433 dampens TGF-ß 
signaling and targets SMAD2 and TGFBR1 RNA. This effect likely contributes to the 
ability of miR-433 to restrain osteoblastic and chondrogenic differentiation, with potential 
implications for bone and cartilage repair. 
 
Introduction 
The appendicular skeleton forms through endochondral ossification, a 
developmental process whereby a cartilage template is gradually replaced by bone. Bone 
tissue itself is also continuously remodeled, in a highly regulated cycle of coupled 
osteoclast-mediated bone resorption followed by osteoblast-mediated bone formation. 
This is the only process whereby adults can renew bone tissue, and it is also critical for 
mineral homeostasis. Prevalent skeletal diseases, such as osteoporosis, are caused by 
an imbalance in bone remodeling.  
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miRNAs are now well appreciated post-transcriptional regulators of both bone and 
cartilage homeostasis. These small non-coding RNAs bind to complementary regions in 
target mRNAs, frequently in the 3’ untranslated region (UTR), resulting in mRNA 
degradation and/or translational suppression. Most miRNAs function to fine tune the 
timing and tempo of gene expression, acting on multiple targets within the same or 
correlated pathways, and causing significant changes in cellular signaling.  
 
Some miRNAs, such as the miR-29 family, have been extensively studied in the 
context of bone and cartilage. miR-29 promotes osteogenesis, in part by targeting 
negative regulators of Wnt signaling (174,175). In cartilage, Sox9, a master transcription 
factor essential for chondrogenic commitment, represses miR-29. The increased levels 
of miR-29 seen in osteoarthritic lesions could contribute to an increase in canonical Wnt 
signaling, thought to play a role in pathogenesis (176,177). These studies illustrate the 
tissue-specific effects of miRNA-29 and its targets in the skeleton. 
 
Although the impact of some miRNAs on the skeleton has been well documented, 
other miRNAs, such as miR-433, are still poorly understood. We initially found that miR-
433 could differentially target a single nucleotide polymorphism (SNP) in osteonectin 
(SPARC). This SNP was associated with bone mass in men with idiopathic osteoporosis 
and caused changes in bone mass in a knock-in mouse model (129-134). In human cells, 
inhibition of miR-433 activity enhanced expression of the osteoblast marker genes 
alkaline phosphatase and osteocalcin (134). Others demonstrated that miR-433 can 
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target Runx2 in the multi-potential C3H/10T1/2 cell line, further suggesting that miR-433 
is a negative regulator of osteoblastic function (101). However, the function of miR-433 in 
chondrogenesis has not been established.  
 
We sought to define the role of miR-433 in mesenchymal lineage commitment and 
differentiation by identifying novel miR-433 targets. We used an in silico approach to 
search for pathways that might be regulated by miR-433, and our analysis suggested that 
several components of the transforming growth factor-ß (TGF-ß) signaling pathway could 
be miR-433 targets. TGF-β is important in osteoblastogenesis, chondrogenesis and 
adipogenesis. TGF-β interacts at the plasma membrane with a receptor dimer consisting 
of one type I and one type II TGF-β receptor. Upon binding of TGF-β, the type II receptor 
transphosphorylates and activates the type I receptor, initiating an intracellular signaling 
cascade involving phosphorylation of SMAD2 and SMAD3. These activated SMADs form 
a complex with SMAD4, allowing translocation into the nucleus and interaction with SMAD 
binding elements (SBEs) and other DNA binding proteins, to activate or repress gene 
transcription (reviewed by (21)).  
 
In other tissues, miRNAs have been shown to target the TGF-β receptors and 
downstream SMADs (178-181). However, information on miRNA regulation of TGF-β 
signaling in skeletal cells is limited. This pathway is of interest because, unlike canonical 
Wnt signaling, TGF-ß appears to play a similar role in bone and cartilage. TGF-ß signaling 
promotes the commitment of progenitors to the osteoblast lineage, but inhibits terminal 
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osteoblast maturation. Likewise, TGF-ß promotes chondrogenesis, but inhibits the 
terminal differentiation stage of hypertrophy. In this study, we defined the expression 
pattern of miR-433 during differentiation of osteoblasts, chondrocytes and adipocytes 
arising from murine bone marrow stromal cells (BMSCs). We demonstrated that miR-433 
limits TGF-β signaling, targets SMAD2 and TGFBR1, and that miR-433 is a negative 
regulator of osteoblastogenesis and chondrogenesis in vitro. 
 
Results 
miR-433 inhibits TGF-β signaling 
We first examined the impact of miR-433 on TGF-β signaling in mesenchymal-like 
cells using the SBE4-luc construct, a well characterized TGF-β-responsive luciferase 
reporter in which four SMAD2/3 binding elements drive expression of luciferase. 
C3H/10T1/2 cells, a multipotent cell line, were cotransfected with the SBE4 construct and 
a non-targeting or miR-433 inhibitor. Cells were treated with vehicle or TGF-β1, and 
luciferase activity was quantified. In cells transfected with a non-targeting inhibitor, TGF-
β1 induced SBE4 promotor activity as expected (Figure 4.1A). Transfection of the miR-
433 inhibitor augmented TGF-β1 activation of the SBE4 promoter, indicating that miR-
433 can inhibit TGF-β signaling.  
 
Bioinformatic analysis suggested that several components of the TGF-β pathway 
could be directly targeted by miR-433, including the TGF-β receptors, TGFBR1 and  
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Figure 4.1. miR-433 inhibits TGF-β signaling and targets SMAD2 and TGFBR1. 
(A) Activity of the TGF-β responsive SBE4 luciferase reporter in C3H/10T1/2 cells co-
transfected with a non-targeting or miR-433 inhibitor. C3H/T101/2 cells were treated with 
vehicle or 5 ng/ml TGF-β1 for 24 hours. (B) Activity of the SMAD2, SMAD4, TGFBR1, and 
TGFBR2 luciferase-3-UTR reporter constructs transiently transfected into C3H/10T1/2 cells, 
along with a miR-433 or non-targeting inhibitor. Potential interaction of miR-433 with (C) the 
TGF-β receptor or (D) SMAD2 and SMAD4 3’ UTRs, as predicted by miRanda (153). Activity 
of (E) SBE4 or (F) target 3’ UTR luciferase reporters in C3H/10T1/2 stably transduced with a 
Doxycycline (Dox)-inducible construct carrying a miR-433 decoy. Cells were treated with 1 
ug/ml Dox for 24 hours, in the presence or absence of 5 ng/ml TGF-β. Luciferase activity is 
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TGFBR2, as well as the downstream signaling components SMAD2 and SMAD4 
(miRanda, TargetScan, RNAhybrid; Figure 4.1C, D). Three of these candidate RNAs 
contained multiple potential miR-433 binding sites. Target gene 3’ UTRs were cloned 
downstream of a constitutively expressed luciferase gene in the reporter plasmid pMIR-
REPORT-Luciferase. The luciferase constructs containing the target 3’ UTRs were 
transiently cotransfected into C3H/10T1/2 cells with a non-targeting or miR-433 inhibitor, 
and luciferase activity was quantified. miR-433 inhibition significantly increased the 
luciferase activity of SMAD2 and TGFBR1 3’ UTR constructs, compared to the non-
targeting control. In contrast, miR-433 inhibitor did not affect SMAD4 and TGFBR2 3’ UTR 
activity (Figure 4.1B). The targeting SMAD2 and TGFBR1 3’ UTR by miR-433 could 
contribute to inhibition of TGF-β signaling.  
 
We had previously developed a stably transduced C3H/10T1/2 cell line in which 
the activity of miR-433 could be knocked down in a Doxycycline (Dox) inducible manner 
(144). These cells express a miR-433 tough decoy (competitive inhibitor), in which a 
green fluorescent protein (GFP) reporter carries 2 miR-433 binding sites in its 3’ UTR 
(156). The activity of this miR-433 decoy phenocopies that of the transiently transfected 
miR-433 inhibitor, with regard to relieving repression of miR-433 targets (182). To confirm 
that the miR-433 decoy mimics the miR-433 inhibitor with respect to TGF-β signaling, the 
SBE4 luciferase reporter and target 3’ UTR constructs were transfected into miR-433 
decoy cells, and cultured in the absence or presence of Dox. Expression of the miR-433 
expressed relative to the vehicle treated non-targeting or no Dox controls.  # = significantly 
different from vehicle, p < 0.05. * = significantly different from non-targeting or no Dox control, 
p < 0.05. (n=12) 
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decoy in the Dox treated cells caused a 2 fold increase in TGF β-induced SBE-4-
luciferase activity, compared with TGF β treated cells cultured in the absence of Dox 
(Figure 4.1E). When examining the activity of the 3’ UTR reporter constructs, increased 
luciferase activity was observed in Dox treated cells that were transfected with SMAD2 or 
TGFBR1 3’ UTR reporter constructs (Figure 4.1F). However, expression of the miR-433 
decoy did not alter activity of the SMAD4 or TGFBR2 3’ UTR constructs. These results 
demonstrate that the miR-433 decoy inhibits miR-433 activity, and confirm miR-433 
regulation of TGF-β signaling. 
 
Since inhibition of miR-433 activity increased expression of the SBE4-luciferase 
reporter, and miR-433 can target the SMAD2 3’ UTR, we examined the impact of miR-
433 on SMAD2 levels and SMAD2 phosphorylation. miR-433 decoy cells were serum 
deprived in the absence or presence of Dox for 24 hours, then treated with vehicle or 1 
ng/ml TGF-β1 for 1 hour. As expected, TGF-β1 increased pSMAD2 in the absence of 
Dox. However, expression of the miR-433 decoy further enhanced TGF-β-induced 
pSMAD2 levels by 1.9 fold (Figure 4.2A, B). Although expression of the miR-433 decoy 
did not alter total SMAD2 levels in vehicle treated cells, treatment with TGF-β increased 
SMAD2 levels in cells expressing the decoy (Figure 4.2C). The presence of the miR-433 
decoy did not alter the ratio of pSMAD2/SMAD2, indicating that the increased pSMAD2 
is due to increased total SMAD2 available for signaling (Figure 4.2D). Overall, these data 
show that miR-433 attenuates TGF-β signaling. 
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Figure 4.2. miR-433 inhibits pSMAD2 and SMAD2 protein levels. 
miR-433 decoy cells were cultured in the absence or presence of 1 ug/ml Dox, in the 
absence of serum for 24 hours. Cells were then treated with 1 ng/ml TGF-β1 for 1 hour 
in the absence or presence of Dox. (A) Representative Western blot. Levels of (B) 
pSMAD2 and (C) SMAD2 normalized to β-actin. (D) Ratio of pSMAD2/SMAD2. # = 
significantly different from vehicle control. * = significantly different from no Dox control, 
p < 0.05. (n=9) 
 
TGF-β downregulates miR-433 
microRNAs often participate in positive or negative feedback loops; because miR-
433 inhibits TGF-β signaling, we determined whether TGF-β could regulate the 
expression of miR-433. C3H/10T1/2 cells were serum deprived for 24 hours and treated 
with 5 ng/ml TGF-β1 for up to 48 hours. In cells treated with TGF-β1, miR-433 expression 
decreased 40% at 24 and 48 hours (Figure 4.3A). In serum-deprived confluent cultures 
of primary mouse BMSCs, treatment with TGF-β1 caused a similar repression of miR-
433 (Figure 4.3B), suggesting a miR-433-TGF-β negative regulatory loop (Figure 4.3C). 
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Figure 4.3. TGF-β represses miR-433 expression 
miR-433 was quantified in (A) C3H/10T1/2 cells and (B) bone marrow stromal cells 
treated with 5 ng/ml TGF-β1 for up to 48 hours. (C) Model for miR-433 and TGF-β1 
interaction. * = significantly different from time matched control, p < 0.05. (n=6) 
 
miR-433 expression decreased during osteogenic differentiation of bone marrow 
stromal cells 
 In C3H/10T1/2 cells, miR-433 was suggested to be a negative regulator of 
osteoblast differentiation (101). However, the expression of miR-433 during osteogenesis 
in primary cells has not been examined. Therefore, primary bone marrow stromal cells 
(BMSCs) were induced to differentiate along the osteoblast lineage by culture in the 
presence of ascorbic acid and β-glycerophosphate for up to 4 weeks. During this process, 
RNA for osteogenic marker genes alkaline phosphatase, Runt-related transcriptional 
factor 2 (Runx2), and osteocalcin, were increased substantially, as was alkaline 
phosphatase activity and deposition of mineralized matrix (Alizarin Red S staining) 
(Figure 4.4A, B). In contrast, miR-433 expression significantly decreased during 
osteogenic differentiation, with a 70% reduction at week 3 (Figure 4.4C). To induce the 
differentiation of C3H/10T1/2 cells towards the osteoblastic lineage, the cells were 
cultured for up to 3 weeks in the presence of 50 ng/ml bone morphogenetic protein  
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 (BMP-2). In these cells, expression 
of miR-433 was also dramatically 
reduced (Figure 4.5; 90.0% decline 
after 1 week of culture), which 
corroborates a previous report 
showing the BMP- 2 induced 
reduction of miR-433 24 hours after 
treatment (101). 
 
 
 
 
 
Figure 4.4 miR-433 decreases during osteogenic differentiation of bone marrow 
stromal cells 
Bone marrow stromal cells were differentiated with 5 mM β-glycerophosphate and 50 
µg/ml ascorbic acid for up to 4 weeks. (A) Alkaline phosphatase (Ap), Runx2, and 
osteocalcin (Oc) mRNA expression. (B) Alkaline phosphatase and Alizarin Red S 
staining. (C) miR-433 expression. * = significantly different from day 0, p < 0.05. (n=8) 
 
Figure 4.5 miR-433 decreases during 
osteogenic differentiation of C3H/10T1/2 
cells 
C3H/10T1/2 miR-433 decoy cells treated with 
no doxycycline were differentiated with 50 
ng/ml BMP-2, 8 mM β-glycerophosphate and 
50 µg/ml ascorbic acid for up to 3 weeks and 
measured for miR-433 expression. * = 
significantly different from day 0, p < 0.05. 
(n=4) 
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miR-433 negatively regulates osteogenesis 
Although it has been previously reported that miR-433 is a negative regulator of 
osteogenesis in C3H10T1/2 cells, osteoblastic gene expression had only been examined 
after an acute (up to 3 days) treatment with BMP-2 (101,134). To better define the impact 
of miR-433 on the regulation of osteogenic differentiation, we cultured  
 
Figure 4.6. miR-433 decoy enhances osteogenic differentiation in vitro 
Non-targeting and miR-433 decoy cells were differentiated with 100 µg/ml ascorbic 
acid, 8 mM β-glycerophosphate, and 50 ng/ml BMP-2 for up to 3 weeks in the 
absence or presence of 1 ug/ml Dox. Alkaline phosphatase (Ap) mRNA expression 
in (A) non-targeting and (B) miR-433 decoy cells. Runx2 mRNA expression in (C) 
non-targeting and (D) miR-433 decoy cells. Osteocalcin mRNA expression in (E) 
non-targeting and (F) miR-433 decoy cells.  # = significantly different from day 0, p 
< 0.05. * = significantly different from corresponding no Dox control, p < 0.05. (n=4)  
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C3H/10T1/2 cells stably transduced with the Dox-inducible non-targeting miRNA decoy 
or miR-433 decoy with a BMP-2-containing osteogenic cocktail for up to 3 weeks. In non-
targeting decoy cells, osteogenic marker genes alkaline phosphatase, Runx2, and 
osteocalcin increased at all time points compared to day 0, and gene expression was not 
altered by the absence or presence of Dox (Figure 4.6A, C, E). In contrast, expression of 
the miR-433 decoy significantly enhanced expression of the early osteoblastic marker 
genes alkaline phosphatase and Runx2, 
with a maximal effect observed at week 3 
(Figure 4.6B, D). Although the miR-433 
decoy significantly enhanced mRNA 
levels for the terminal osteoblast 
differentiation marker osteocalcin at all 
time points, the effect was not as robust 
as that observed with the earlier markers 
(Figure 4.6F). Moreover, miR-433 
inhibition also increased mineralized 
matrix production (1.5 ± 0.1 fold at week 
3; p<0.05). Growth curves for the non-
targeting and miR-433 decoy cells cultured in the presence or absence of Dox were 
superimposable, suggesting that enhanced cell number did not play a role in the observed 
effects (Figure 4.7). Overall, miR-433 appears to be a negative regulator of osteoblastic 
differentiation in vitro, with a particularly strong impact on early osteogenesis.  
 
 
Figure 4.7. The non-targeting and miR-
433 decoy does not alter cell 
proliferation.  
C3H/10T1/2 cells transduced with a non-
targeting or miR-433 decoy were cultured 
in the absence or presence of 1000 ng/ml 
Dox for up to 96 hours and were assessed 
by MTS assay read at 490 nm. (n=12) 
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miR-433 is unchanged during adipogenesis 
 Osteoblasts and adipocytes arise from a common progenitor in the bone marrow, 
and marrow adipogenesis is often inversely correlated with bone mass (183). Indeed, 
TGF-β is a negative regulator of adipogenesis, inhibiting the transactivation of  
 
CCAAT/enhancer binding protein α (Cebpα), a critical pro-adipogenic transcription factor 
(184). Therefore, we next examined miR-433 expression during the adipogenic 
differentiation of BMSCs, stimulated by culture in a cocktail containing rosiglitazone and 
insulin for up to 9 days. mRNA levels for Cebpα, peroxisome proliferator activated 
receptor gamma (Pparγ), and fatty acid binding protein 4 (Fabp4) were examined as  
 
Figure 4.8. miR-433 expression is not altered during adipogenic differentiation 
of bone marrow stromal cells  
Bone marrow stromal cells were differentiated with 500 nM rosiglitazone and 1 µM 
insulin for up to 9 days. (A) CCAAT enhanced binding protein α (Cebpα), peroxisome 
proliferator activated receptor gamma (Pparγ), and fatty acid binding protein 4 (Fabp4) 
mRNA expression. (B) miR-433 expression. (C) Oil Red O staining. * = significantly 
different from day 0, p < 0.05. (n=8) 
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markers of adipogenesis. The adipocyte 
differentiation protocol significantly 
induced adipogenic marker genes at all 
time points compared to day 0 (Figure 
4.8A). Oil red O staining showed 
increasing lipid droplet accumulation 
throughout the 9 day differentiation (Figure 
4.8C). However, miR-433 expression was 
not significantly changed over the course 
of adipogenic differentiation of BMSCs or 
C3H/10/1/2 cells (Figure 4.8B, Figure 4.9).  
 
miR-433 does not alter adipogenic differentiation 
 Although miR-433 expression was unchanged during adipogenesis, it could still 
potentially play a role in regulating adipogenic differentiation. To examine this, non-
targeting and miR-433 decoy cells were differentiated toward the adipogenic lineage with 
rosiglitazone and insulin, in the absence or presence of Dox. In non-targeting decoy cells, 
Cebpα, Pparγ, and Fabp4 mRNA expression were induced, and they were not altered by 
treatment with Dox (Figure 4.10A, C, E). In miR-433 decoy cells, the expression of 
adipogenic marker genes were the same in the presence or absence of Dox (Figure 
4.10B, D, F), indicating that miR-433 does not regulate adipogenic differentiation.  
 
Figure 4.9. miR-433 expression is not 
altered during adipogenic 
differentiation of C3H/10T1/2 cells. 
C3H/10T1/2 cells were differentiated with 
500 nM rosiglitazone and 1 µM insulin for 
up to 9 days and examined for miR-433 
expression. (n=8) 
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Figure 4.10. miR-433 inhibition does not alter adipogenesis 
Non-targeting and miR-433 decoy cells were differentiated with 500 nM rosiglitazone and 
1 µM insulin for up to 9 days in the absence of presence of 1 ug/ml Dox. Cebpα mRNA 
expression in (A) non-targeting and (B) miR-433 decoy cells. Pparγ mRNA expression in 
(C) non-targeting and (D) miR-433 decoy cells. Fabp4 mRNA expression in (E) non-
targeting and (F) miR-433 decoy cells. Quantification of lipid droplet formation by Oil Red 
O staining in (G) non-targeting and (H) miR-433 decoy cells. # = significantly different 
from day 0, p < 0.05. (n=4). 
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miR-433 expression increases during chondrogenic differentiation 
TGF-β is a crucial mediator of chondrogenic differentiation. Since miR-433 is a 
negative regulator of TGF-β signaling, we next examined miR-433 expression in BMSCs 
cultured in high density micromasses and differentiated with a chondrogenic cocktail 
 
Figure 4.11. miR-433 expression increases during chondrogenic differentiation 
of bone marrow stromal cells and iPSC derived mesenchymal cells 
(A) Sox9, Col2a1, and ColXa1 mRNA, (B) miR-433 expression, and (C) Alcian Blue 
staining in bone marrow stromal cells differentiated with a chondrogenic cocktail 
containing 10 ng/ml TGF-β1 for up to 18 days. (D) Sox9 and Col2a1 mRNA, (E) miR-
433 expression, and Alcian Blue staining in mesenchymal cells derived from human 
iPSCs differentiated with a chondrogenic cocktail containing 100 ng/ml BMP-2 for up 
to 21 days.  * = significantly different from day 0, p < 0.05. (n=4) 
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containing TGF-β1 and BMP-2. Expression of the early chondrogenic marker gene Sox9 
increased first, followed by induction of the later chondrogenic genes type 2 
collagen a1 (Col2a1) and type 10 
collagen a1 (ColXa1), and the 
production of proteoglycans 
measured by Alcian Blue staining 
(Figure 4.11A, E). miR-433 
expression increased substantially 
during chondrogenic differentiation, 
with a 14 fold induction by 18 days of 
differentiation in comparison to day 0 
(Figure 4.11C). miR-433 expression 
was similarly, although less 
dramatically induced during the 
chondrogenic differentiation of C3H/10T1/2 cells (Figure 4.12). 
 
Induced pluripotent stem cells (iPSCs) show promise for clinical applications in the 
repair of cartilage defects. Indeed, iPSC derived-MSCs can be potently differentiated 
towards the chondrogenic lineage (185). To determine whether miR-433 expression 
showed a similar response in human cells, we examined a previously characterized skin 
dermal fibroblast-derived iPSC line (185). The MSC-like progenitors derived from iPSCs 
were cultured in high density micromasses with a chondrogenic cocktail containing BMP-
2, and expression of chondrocyte markers and miR-433 was examined. Sox9 and Col2a1 
 
Figure 4.12. miR-433 expression increases 
during chondrogenic differentiation of 
C3H/10T1/2 cells 
miR-433 decoy cells were differentiated a 
chondrogenic cocktail containing 10 ng/ml 
TGF-β1 and 100 ng/ml BMP-2 for up to 14 days 
in the absence Dox and measured for miR-433 
expression. * = significantly different from day 
0, p < 0.05 (n=4) 
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mRNA expression, and proteoglycan synthesis, were significantly increased with 
chondrogenic differentiation (Figure 4.12D, F), and miR-433 was significantly increased 
at all time points compared to day 0, reaching a 14 fold induction by day 21 of 
differentiation, as seen in the mouse BMSCs (Figure 4.12E). This demonstrates that miR-
433 levels increase during chondrogenesis in both murine and human cells. 
 
miR-433 restrains chondrogenesis 
To examine the role of miR-433 in chondrocytes, non-targeting and miR-433 decoy 
cells were grown as micromasses, cultured under chondrogenic conditions, and 
examined for chondrocyte marker genes and proteoglycan deposition. Sox9, Col2a1, and 
ColXa1 mRNA expression in non-targeting decoy cells increased significantly at all time 
points, and culture in the presence of Dox did not affect chondrogenic marker gene 
expression (Figure 4.13A, C, E). In the absence of Dox, miR-433 decoy cells showed a 
similar response in chondrocyte marker mRNA expression. However, miR-433 inhibition 
potently enhanced expression of the early marker Sox9 mRNA at days 7 and 10 (Figure 
4.13B). The miR-433 decoy appreciably increased Col2a1 mRNA by day 7, an effect 
sustained through day 14 (Figure 4.13D). miR-433 inhibition also increased mRNA for the 
hypertrophic marker ColXa1 at days 7 and 14 (Figure 4.13F). As seen with osteoblasts, 
miR-433 also suppressed chondrogenic differentiation. 
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Figure 4.13. miR-433 inhibition induces chondrogenic differentiation 
Non-targeting and miR-433 decoy cells were differentiated a chondrogenic cocktail 
containing 10 ng/ml TGF-β1 and 100 ng/ml BMP-2 for up to 14 days in the absence of 
presence of 1 ug/ml Dox. Sox9 mRNA expression in (A) non-targeting and (B) miR-
433 decoy cells. Col2a1 mRNA expression in (C) non-targeting and (D) miR-433 decoy 
cells. ColXa1 mRNA expression in (E) non-targeting and (F) miR-433 decoy cells. (G) 
miR-433 decoy cells stained with Alcian Blue in the absence or presence of Dox. # = 
significantly different from day 0, p < 0.05. * = significantly different from corresponding 
no Dox control, p < 0.05. (n=4) 
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miR-433 promotes trabecular bone volume and suppresses SMAD2 and TGFBR1 
mRNA in vivo 
Since miR-433 
inhibition enhanced 
osteoblast gene marker 
expression in vitro, we next 
developed an in vivo model to 
determine if miR-433 plays a 
similar role in regulating the 
skeleton. We created 
transgenic mice in which the 
miR-433 decoy, contained 
within the 3’ UTR of the red 
fluorescent reporter gene 
tdTomato, was expressed 
under the control of a 3.6 kb fragment of the rat Col1a1 promoter (miR-433 decoy mice). 
We obtained 3 germline founders (A, B, and C). Expression of the tdTomato-miR-433 
decoy in 8 week old male calvaria was determined by qRT-PCR. TdTomato mRNA from 
miR-433 decoyCol1a1 mice demonstrated similar transgene expression in lines B and C, 
whereas transgene expression in line A is ~5 fold lower (Figure 4.14). As expected, frozen 
sections show the decoy (tdTomato signal) is expressed in periosteum, endosteum, 
trabecular osteoblasts, and early osteocytes in both male and female mice at 8 weeks 
(Figure 4.15).  
 
Figure 4.14. Transgene expression in 3 germlines.  
Calvaria were isolated from 8 week old male transgenic 
mice expressing the miR-433 decoy under the control 
of a Col1a1 promoter (miR-433 decoyCol1a1 mice) and 
wild type litter mate controls between 3 germlines. 
TdTomato mRNA were quantified in calvaria at ZT13 
and compared to WT littermates. n=7. * = significantly 
different germline A, p < 0.05. 
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 Our in vitro studies indicated that miR-433 targets SMAD2 and TGFBR1 and 
inhibits TGF-β signaling.  To determine whether miR-433 plays a similar role in the 
regulation of the TGF-β signaling in vivo, we examined SMAD2 and TGFBR1 mRNA 
expression in miR-433 decoyCol1a1 mice. In 8 week old male mice, the presence of the 
miR-433 decoy enhanced SMAD2 and TGFBR1 mRNA expression by 2 and 1.65 fold,  
 
Figure 4.15. Frozen section from miR-433 decoyCol1a1 mice. 8 week old mouse femur 
from female and male. Red=tdTomato from decoy; green=calcien; blue/teal=DAPI 
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respectively 
(Figure 4.16).  Inhibition 
of miR-433 activity 
increased the 
expression of TGF-β 
signaling components 
in vivo, corroborating 
our in vitro results.   
 
 
Using micro CT, 
we analyzed the 
trabecular and cortical phenotype in femurs of male and female miR-433 decoyCol1a1 mice 
at 4 and 8 weeks of age and compared them to matched littermate controls. The first thing 
we noted was that each transgenic line displayed a similar bone phenotype, suggesting 
that the level of transgene expression in Line A is sufficient. Therefore, we combined the 
data from the 3 lines in our subsequent analyses. 
 
Figure 4.16. miR-433 inhibits SMAD2 and TGFBR1 mRNA 
expression in vivo.  
Calvaria were isolated from 8 week old male transgenic mice 
expressing the miR-433 decoy under the control of a Col1a1 
promoter (miR-433 decoyCol1a1 mice) and wild type litter mate 
controls. SMAD2 and TGFBR1 mRNA were quantified in 
calvaria at ZT13. n=7. * = significantly different WT 
littermates, p < 0.05.  
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At 4 weeks of age, female miR-433 decoyCol1a1 and WT littermates displayed similar 
trabecular bone parameters (Table 4.2). In contrast, 4 week old miR-433 decoyCol1a1 male 
mice had a marked reduction in trabecular bone, with a 20% reduction in BV/TV (Table 
4.1). Trabecular thickness and number were also significantly decreased in miR-433 
decoyCol1a1 mice, with increased 
trabecular spacing (Table 4.1). In miR-
433 decoyCol1a1 mice, multiple bone 
parameters were also markedly 
decreased, including connective 
density, apparent density, tissue 
density, total volume, and bone volume 
(Table 4.1). SMI (structural model 
index) evaluation suggested that 
trabecular bone in miR-433 decoyCol1a1 
mice also has an increased cylindrical 
structure compared to WT mice (Table 
4.1). Cortical measurements in 4 week 
old male mice revealed no significant differences between miR-433 decoyCol1a1 and WT 
mice. Overall, miR-433 increases trabecular bone in 4 week old male mice, but does not 
affect female mice. At 8 weeks of age, no significant differences were observed in male 
or female mice in trabecular or cortical bone in miR-433 decoyCol1a1 and WT mice (Table 
4.3, 4.4).   
 
 
Figure 4.17. Representative microCT 
image of trabecular and cortical bone in 4 
week old male miR-433 decoyCol1a1 mice.  
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Table 4.1. Male Trabecular Bone Measurements. * = p < 0.05. ** = p < 0.01. *** = p < 
0.001. 
Age 4 week  8 week 
Genotype WT miR-433 
DecoyCol1a1 
WT miR-433 
DecoyCol1a1 
 n=16 n=18 n=8 n=10 
Bone Parameters     
BVF (Bone Volume/Total 
Volume) (%) 
12.8 ± 2.80 10.0 ± 1.70*** 15.9 ± 3.6 16.4 ± 5.90 
Trab. Thickness (µM) 51.0 ± 5.00 46.4 ± 2.40*** 57.0 ± 4.4 53.9 ± 7.90 
Trab. Number (1/mm) 4.81 ± 0.29 4.39 ± 0.35*** 4.92 ± 0.63 5.11 ± 0.58 
Trab. Spacing (µM) 210  ± 13.0 232  ± 20.0*** 204  ± 31.0 195  ± 26.0 
Connect. Density 
(1/mm^3) 
93.0 ± 22.0 75.1 ± 22.5** 109  ± 35.7 111  ± 38.2 
Apparent Density (mg/ccm 
HA) 
131  ± 15.0 112  ± 11.4*** 190  ± 32.9 183  ± 43.2 
Tissue Density (mg/ccm 
HA) 
627  ± 19.0 613  ± 26.0* 814  ± 15.0 786  ± 35.0 
Total Volume (TV, mm^3) 1.17 ± 0.09 1.13 ± 0.09 1.82 ± 0.23 1.78 ± 0.25 
Bone Volume (BV, mm^3) 0.15 ± 0.03 0.11 ± 0.02*** 0.29 ± 0.09 0.30 ± 0.13 
Structural Model Index 2.80 ± 0.20 3.00 ± 0.18* 2.48 ± 0.32 2.41 ± 0.51 
Bone Surface (BS, mm^2) 6.60 ± 1.10 5.40 ± 0.97*** 12.1 ± 3.48 12.3 ± 4.13 
BS/BV (mm^2) 53.0 ± 6.30 58.8 ± 3.73** 46.5 ± 4.72 49.7 ± 11.0 
BS/TV (1/mm) 5.60 ± 0.80 4.75 ± 0.70*** 6.56 ± 1.34 6.76 ± 1.71 
BS/MV (1/mm) 6.50 ± 1.20 5.29 ± 0.89*** 7.87 ± 1.85 8.25 ± 0.14 
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Table 4.2. Female Trabecular Bone Measurements 
Age 4 week  8 week 
Genotype WT miR-433 
DecoyCol1a1 
WT miR-433 
Decoy Col1a1 
 n=10 n=6 n=9 n=11 
Bone Parameters     
BVF (Bone 
Volume/Total Volume) 
(%) 
7.3 ± 1.50 8.2  ± 1.00 5.50  ± 0.80 5.50  ± 1.30 
Trab. Thickness (µM) 45.0 ± 1.50 45.7 ± 2.10 40.6 ± 1.20 40.5 ± 3.30 
Trab. Number (1/mm) 3.87 ± 0.51 4.10 ± 0.56 3.67 ± 0.29 3.64 ± 0.24 
Trab. Spacing (µM) 265  ± 33.0 252  ± 33.0 278  ± 23.0 277  ± 18.0 
Connect. Density 
(1/mm^3) 
47.4 ± 14.8 52.9 ± 11.1 24.4 ± 7.92 26.1 ± 14.6 
Apparent Density 
(mg/ccm HA) 
95.2 ± 11.3 101  ± 7.30 88.9 ± 10.5 82.1 ± 10.7 
Tissue Density 
(mg/ccm HA) 
615  ± 22.0 610  ± 27.0 792  ± 24 790  ± 29.0 
Total Volume (TV, 
mm^3) 
1.09 ± 0.09 1.08 ± 0.08 1.50 ± 0.12 1.48 ± 0.12 
Bone Volume (BV, 
mm^3) 
0.08 ± 0.02 0.09 ± 0.01 0.08 ± 0.01 0.08 ± 0.02 
Structural Model Index 3.19 ± 0.18 3.07 ± 0.17 3.38 ± 0.14 3.35 ± 0.23 
Bone Surface (BS, 
mm^2) 
3.85 ± 1.05 4.26 ± 0.61 4.11 ± 0.57 4.08 ± 0.99 
BS/BV (mm^2) 60.9 ± 2.10 59.5 ± 4.25 66.7 ± 2.21 67.4 ± 5.38 
BS/TV (1/mm) 3.48 ± 0.75 3.94 ± 0.47 2.74 ± 0.42 2.76 ± 0.62 
BS/MV (1/mm) 3.76 ± 0.86 4.29 ± 0.55 2.91 ± 0.47 2.92 ± 0.71 
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Table 4.3. Male Cortical Bone Measurements 
Age 4 week  8 week 
Genotype WT miR-433 
DecoyCol1a1 
WT miR-433 
Decoy Col1a1 
 n=16 n=18 n=8 n=10 
Bone Parameters     
Length (mm) 11.5 ± 0.40 11.6 ± 0.300 14.1 ± 0.50 14.1 ± 0.40 
Sub-periosteal area 
(mm^2) 
1.35 ± 0.13 1.31 ± 0.05 1.80 ± 0.17  1.80 ± 0.20 
Sub-endosteal area 
(mm^2) 
0.95 ± 0.08 0.93 ± 0.03 1.07 ± 0.10 1.07 ± 0.12 
Cortical Mask (mm^2) 0.40 ± 0.06 0.37 ± 0.03 0.72 ± 0.07  0.73 ± 0.10 
Segmented Bone 
(mm^2) 
0.34 ± 0.05 0.32 ± 0.03 0.72 ± 0.07  0.73 ± 0.10 
Periosteal Perimeter 
(mm) 
3.06 ± 0.25 3.01 ± 0.18 4.48 ± 0.39 4.47 ± 0.42 
Endosteal Perimeter 
(mm) 
3.45 ± 0.14 3.42 ± 0.06 3.67 ± 0.18 3.65 ± 0.19 
Cortical Porosity 
(mm^2) 
0.05 ± 0.00 0.05 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Cortical Thickness 
(mm)  
0.08 ± 0.01 0.08 ± 0.01 0.16 ± 0.01 0.16 ± 0.02 
Polar Moment of 
Inertia (MOI) (mm^4) 
0.13 ± 0.03 0.12 ± 0.01 0.35 ± 0.06 0.36 ± 0.08 
Max MOI (mm^4) 0.08 ± 0.02 0.07 ± 0.01 0.23 ± 0.04 0.24 ± 0.05 
Min MOI (mm^4) 0.05 ± 0.01 0.05 ± 0.00 0.12 ± 0.02 0.12 ± 0.03 
 
  
99 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4.4. Female Cortical Bone Measurements 
Age 8 week 
Genotype WT miR-433  
Decoy Col1a1 
 n=9 n=11 
Bone Parameters   
Length (mm) 14.1 ± 0.53 14.1 ± 0.43 
Sub-periosteal area 
(mm^2) 
1.80 ± 0.17 1.80 ± 0.20 
Sub-endosteal area 
(mm^2) 
1.08 ± 0.10 1.06 ± 0.11 
Cortical Mask (mm^2) 0.72 ± 0.08 0.74 ± 0.10 
Segmented Bone 
(mm^2) 
0.70 ± 0.08 0.73 ± 0.10 
Periosteal Perimeter 
(mm) 
4.48 ± 0.39 4.47 ± 0.42 
Endosteal Perimeter 
(mm) 
3.67 ± 0.18 3.66 ± 0.19 
Cortical Porosity 
(mm^2) 
0.00 ± 0.00 0.00 ± 0.00 
Cortical Thickness 
(mm)  
0.16 ± 0.01 0.16 ± 0.02 
Polar MOI (mm^4) 0.35 ± 0.06 0.36 ± 0.08 
Max MOI (mm^4) 0.23 ± 0.04 0.24 ± 0.05 
Min MOI (mm^4) 0.12 ± 0.02 0.12 ± 0.03 
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Discussion 
TGF-β is an essential growth factor directing lineage commitment of mesenchymal 
cells. In this study, we identified miR-433 as a negative regulator of TGF-β signaling, and 
demonstrated novel miR-433 targets in vitro and in vivo, SMAD2 and TGFBR1. In 
addition, we identified 3 distinct patterns of miR-433 expression with cell lineage 
progression: decreased expression during osteogenesis, unchanged expression during 
adipogenesis, and increased expression during chondrogenesis. Moreover, we confirmed 
that miR-433 serves to limit differentiation of osteoblasts, but does not affect 
adipogenesis. However, the function of miR-433 in vivo is important for trabecular bone 
volume in growing male mice, whereas it does not appear to impact bone in young female 
mice. Most promising, we identified miR-433 as a potent inhibitor of chondrogenesis. 
Strategies aimed at inhibiting miR-433 activity could represent a novel avenue for the 
stimulation of cartilage formation. 
 
Information on the mechanisms regulating miR-433 expression is limited. 
Transcription of the miR-433 locus is induced by orphan receptor estrogen related 
receptor γ (ERRγ), a repressor of osteogenesis, and negative regulator of chondrocyte 
proliferation (186). In contrast, miR-433 transcription can be repressed by small 
heterodimer partner (SHP, NR0B2), which promotes osteoblast differentiation 
(101,169,170). The miR-433 promoter also contains CpG islands, and changes in 
promoter methylation status have been shown to contribute to its regulation in cancer 
cells (187). Although miR-433 expression is increased in osterix-null mouse calvaria, 
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direct regulation of the miR-433 promoter by osterix was not demonstrated (188). The 
molecular mechanisms regulating miR-433, particularly during chondrogenesis, remain 
to be determined. 
 
TGF-ß plays an important but complex role at every stage of bone formation. TGF-ß 
promotes osteoblast proliferation and acts as a chemoattractant during early stages of 
differentiation, but inhibits terminal differentiation by suppressing alkaline phosphatase 
and osteocalcin, as well as suppressing matrix mineralization (22,189-191). Thus, the 
timing and intensity of TGF-ß signaling needs to be tightly controlled for optimal 
osteoblast function. miRNAs often function to fine tune the expression of their targets, 
and in the case of miR-433, it could play a role in moderating the TGF-ß response during 
osteogenic differentiation, to ensure an optimal level of signaling. However, the regulation 
of osteogenesis by miR-433 is not limited to TGF-ß mediated mechanisms. miR-433 was 
previously shown to target Runx2, Igf-1, osteonectin, and glucocorticoid receptor mRNA, 
all of which play important roles during osteogenic differentiation (101,134,182). miR-433 
likely restrains osteogenic differentiation in vitro by inhibiting multiple pathways important 
for differentiation. 
 
Given the cell autonomous actions of miR-433 identified in vitro, it was somewhat 
surprising to find that inhibition of miR-433 activity in vivo resulted in decreased trabecular 
bone volume in males. In miR-433 decoyCol1a1 male mice at 4 weeks of age, the trabecular 
bone compartment had reduced BV/TV, trabecular number and thickness, with increased 
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trabecular spacing. By 8 weeks of age, the trabecular bone phenotype in miR-433 
decoyCol1a1 mice was normalized. It is also possible that enhanced TGFβ signaling in cells 
expressing the miR-433 decoy could lead to the accumulation of osteoid that is later 
mineralized. We recently demonstrated that miR-433 can attenuate glucocorticoid 
signaling. The miR-433 decoyCol1a1 mice may have upregulated glucocorticoid signaling, 
and it is well documented that glucocorticoid excess decreases bone formation (reviewed 
by (81); (192)). It is also possible that miR-433 could be targeting pathways that are more 
important in growing mice than in adults. For example, knockdown of parathyroid receptor 
signaling in mice at 4 weeks of age reduced osteoblast number to a greater extent than 
when the receptor was knocked down at 8 weeks (193). However, since the activity of the 
Col1a1 promoter-driven transgene is higher in growing mice than in adults, it is very likely 
reduced transgene expression in the 8 week old mice contributes to the normalization of 
the trabecular bone phenotype (162,194).  
 
In contrast to the male mice, our microCT analysis did not demonstrate a bone 
phenotype in female miR-433 decoyCol1a1 mice. This could be due to multiple reasons. 
One reason may be due to a lower sample number of female miR-433 decoyCol1a1 mice 
analyzed at 4 weeks of age. We may potentially see more modest differences by 
increasing the sample size. Alternatively, since female C57BL/6 mice lose trabecular 
bone volume with age, analysis of older female mice may be revealing. Additionally, there 
could be a differential role of miR-433, or differential expression, between male and 
female mice. Another potential reason for differences between the sexes could be the 
result of higher glucocorticoid levels in female mice, suggesting that males might be more 
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sensitive to smaller variations in glucocorticoid signaling (195,196).  
 
Calvarial bone from miR-433 decoyCol1a1 mice had increased SMAD2 and TGFBR1 
mRNA expression, and we previously demonstrated that they have increased Runx2 and 
osteocalcin mRNA, suggesting that miR-433 may, indeed, be a negative regulator of bone 
formation. Yet, trabecular bone volume was decreased in growing miR-433 decoyCol1a1 
male mice This suggests there may be potential alterations in miR-433 regulation of the 
skeleton depending on the age of mice, or that there may be differential regulation 
between the calvaria and femur bones. Further analysis of bone formation rate and 
osteoclastic parameters is needed to fully understand the role of miR-433 in the skeleton.  
 
TGF-β is also a potent inducer of chondrogenesis (reviewed by (25)). TGF-β promotes 
type II collagen synthesis through the interaction of SMAD2/3 with Sox9 on type II 
collagen enhancer elements (31). However, TGF-β can inhibit chondrocytes from 
terminally differentiating into hypertrophic chondrocytes, reducing extracellular matrix 
mineralization (reviewed by (25)). miR-433 expression is profoundly induced during 
chondrogenic differentiation of both murine and human cells. Moreover, this increase in 
miR-433 was observed using chondrogenic differentiation cocktails that contained TGF-
ß and those that lacked TGF-ß, suggesting a fundamental, well conserved mechanism.  
 
During early stages of chondrogenesis, low levels of miR-433 could help augment the 
TGF-ß response, while at later stages, where miR-433 expression is highest, this miRNA 
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could weaken the TGF-ß response to allow progression towards hypertrophy. That 
TGFBR1 is decreased with chondrocyte hypertrophy of BMSCs reinforces the concept 
that TGF-ß signaling should be limited during this phase (197). As with osteoblasts, miR-
433 likely targets other pathways important for chondrogenesis, contributing to its role as 
a repressor of differentiation.  
 
In humans, miR-433 has been linked to a form of dominant X-linked chondrodysplasia, 
in which a histone deacetylase 6 (HDAC6) 3’ UTR variant causes a change in miR-433 
seed region targeting (135). Affected patients have increased HDAC6 protein levels due 
to altered miR-433 binding, suggesting that miR-433 levels could regulate acetylation of 
HDAC6 targets (135). In mice, overexpression of HDAC4, a class II HDAC related to 
HDAC6, prevents mineralization of hypertrophic chondrocytes and causes shortened 
limbs, due the altered acetylation of the Runx2 promoter, which decreases its activity 
(198). HDAC6 and Runx2 have been found to interact together in osteoblasts (199). It is 
possible that targeting of HDAC6 by miR-433 could contribute to its actions in 
chondrogenic differentiation by affecting acetylation and thus transcriptional regulation of 
downstream targets.  
 
In extra-skeletal tissues, miR-433 was shown to promote renal fibrosis, and that miR-
433 expression is increased in response to TGF-ß in kidney tubular epithelial cells 
(200,201). In these studies, SMAD3 promoted the expression of miR-433, whereas 
SMAD2 repressed miR-433 levels (200). Functional SMAD binding sites were identified 
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in the miR-433 proximal promoter, suggesting direct regulation, although the induction of 
miR-433 by TGF-ß in these studies was not observed until 12 hours post treatment. In 
contrast, we showed that TGF-ß decreased the expression of miR-433 in mesenchymal 
lineage cells after 24 hours of treatment. The differential regulation of miR-433 by TGF-ß 
is likely cell type specific, possibly related to differences in SMAD2 vs SMAD3 signaling 
in mesenchymal and epithelial cells. The delay in the response of miR-433 to TGF-ß in 
mesenchymal cells could suggest a requirement for prolonged TGF-ß signaling, or an 
indirect effect of TGF-ß on miR-433 transcription, or could reflect the time needed for the 
turnover of existing miR-433, since miRNAs are, in general, fairly stable (202,203). Within 
the skeleton, a TGF-ß-miR-433 negative regulatory loop could allow for the renewal of 
cell sensitivity to TGF-ß.  
 
There are multiple skeletal pathologies in which defects in TGF-ß regulation are 
implicated. For example, over activation of TGF-ß signaling is important in the 
pathogenesis of connective tissue disorders such as Loeys-Dietz syndrome, Marfan 
syndrome, and Camurati-Engelmann disease (204-206). Moreover, TGF-ß released from 
the bone matrix plays a supportive role in the survival of bone metastatic breast cancer 
cells and multiple myeloma cells (207). In fracture repair, osteoprogenitors migrate and 
respond to TGF-ß released from bone and platelets (208,209). Identifying miR-433 
targets in the TGF-ß signaling pathway enhances to our understanding of the possible 
function of miR-433 in these diseases, as well as comprehending its function in other 
tissues expressing miR-433, such as liver, cartilage, brain, and immune cells 
(126,135,210-212). 
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Overall, we show that miR-433 targets SMAD2 and TGFBR1, and downregulates 
TGF-ß signaling. This likely contributes to the inhibitory effect of miR-433 on osteoblastic 
and chondrogenic differentiation. These findings add to our understanding of how 
miRNAs regulate differentiation and their impact on skeletal development and 
remodeling.  
 
Materials and Methods. 
Mice 
C57BL/6 male mice were provided with food and water ad libitum. All animal 
protocols were reviewed and approved by the UConn Health Institutional Animal Care 
and Use Committee (IACUC). 
We created mice expressing a transgene in which a 3.6 kb fragment of the rat 
col1A1 promoter, plus 1.6 kb of the first intron drive expression of the tdTomato reporter 
gene carrying a miR-433 tough decoy (TuD) in its 3’ UTR (custom synthesis, GenScript, 
Piscataway, NJ) (156,162). Mice were generated in a C57BL/6 background by pronuclear 
injection of the transgene cassette at the UConn Health Gene Targeting and Transgenic 
Facility. The miR-433 decoy serves as a competitive inhibitor of miR-433 activity, relieving 
the suppression of endogenous miR-433 targets.  
 
Cell culture and cell proliferation 
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C3H/10T1/2, Clone 8, a multipotent mouse mesenchymal cell line, was obtained 
from the American Type Culture Collection (ATCC® CCL-226™) and cultured in DMEM 
(Gibco Life Technologies, Carlsbad, CA) supplemented with 10% heat-inactivated Fetal 
Bovine Serum (FBS, Lonza, Basel, Switzerland) and 1% penicillin-streptomycin. Primary 
bone marrow stromal cells (BMSCs) were flushed from the long bones of 8 week old male 
C57BL/6 mice by centrifugation and maintained in αMEM supplemented with 10% FBS 
and 1% penicillin-streptomycin (213). 
  
Mesenchymal stem cell (MSC)-like cells were derived from human dermal 
fibroblast iPSC line (HDFa-YK26), as previously described (21). iPSC-derived MSCs 
were maintained in growth media consisting of DMEM-HG (Gibco Life Technologies, 
Carlsbad, CA), 10% defined FBS (Hyclone), 1% nonessential amino acids, 5 ng/mL 
human recombinant bFGF (Invitrogen), and 1% penicillin-streptomycin.  
 
Cell proliferation was assessed on days 1 through 4 post-plating, using MTS 
CellTiter 96 Aqueous One solution cell proliferation assay kit (Promega, Madison, WI), 
according to manufacturer’s instructions.  Cells were plated at 5,000 cells/well and were 
treated in the absence or presence of 1 µg/ml Dox in DMEM with 10% FBS and 1% 
Penicillin/Streptomycin.  
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Osteogenic, chondrogenic, and adipogenic differentiation  
For osteogenic differentiation of BMSCs, αMEM was supplemented with 10% FBS, 
5 mM β-glycerophosphate (Sigma-Aldrich) and 50 µg/ml ascorbic acid (Sigma-Aldrich), 
once cells had reached confluence. For osteogenic differentiation of C3H/10T1/2 cells, 
DMEM was supplemented with 10% FBS, 8 mM β-glycerophosphate, 100 µg/ml ascorbic 
acid, 2 µM purmorphamine (Sigma-Aldrich), and 50 ng/ml BMP (gift from Medtronic). 
Calcium deposition was measured by staining cells with 1% alizarin red S pH 6.45 
(Sigma-Aldrich). Alizarin red stain was extracted and quantified at absorbance 405 nm 
(134). Cells were stained for alkaline phosphatase activity using an Alkaline Phosphatase 
kit (#86R, Sigma-Aldrich).  
 
Adipogenic differentiation was achieved by culturing cells in αMEM supplemented 
with 10% FBS, 500 nM rosiglitazone (Sigma-Aldrich) and 1 µM insulin (Sigma-Aldrich). 
Cells were stained with 0.5% Oil Red O solution, extracted with 100% isopropanol, and 
absorbance was measured at 492 nm. 
 
For chondrogenic differentiation of BMSCs and C3H/10/T1/2 cells, cells were 
cultured in high density micromasses (2x105 cells/10uL drop) in wells coated with 0.1% 
gelatin. Twenty-four hours after micromass formation, culture media was replaced with 
chondrogenic media consisting of αMEM supplemented with 1% insulin-transferrin-
selenium, 40 µg/ml L-proline, 50 µg/ml ascorbic acid, 100 nM dexamethasone (Sigma-
Aldrich), 1 mM sodium pyruvate (ThermoScientific), 1% non-essential amino acids, 10 
109 
 
ng/ml TGF-β1 (R&D Systems), and 100 ng/ml BMP (Medtronic). iPSC-MSCs were 
differentiated in the same chondrogenic cocktail, but excluding TGF-β1 (185). Micromass 
cultures were fixed in 10% formalin, then stained with 1% Alcian Blue (Sigma-Aldrich) in 
acetic acid to visualize proteoglycan synthesis after 14 days of differentiation. 
 
Establishment of a stable inducible miR-433 knockdown model 
To knockdown activity of miR-433, C3H/10T1/2 cells were transduced using 
lentiviral constructs in which a doxycycline (Dox)-inducible promoter drives expression of 
a miR-433 tough decoy (custom synthesis, GenScript). The miR-433 decoy acts as a 
competitive inhibitor for endogenous miR-433 activity because it contains complementary 
miR-433 binding sites. Briefly, the miR-433 decoy was subcloned into the single 
lentivector for inducible knockdown (pSLIK) system and confirmed by sequencing (144) 
(Addgene, Cambridge, MA). This vector contains a ubiquitin C promoter driving 
constitutive expression of reverse Tet transactivator (rtTA3). Doxycycline treatment 
stimulates the rtTA to drive transcription of TRE, allowing for inducible expression of the 
decoy. A non-targeting tough decoy was developed as a control. The non-targeting decoy 
contains C. elegans miR-67 binding sites (custom synthesis, GenScript), which are not 
predicted to interact with mammalian miRNAs. Cells stably transduced with the pSLIK-
miR-433 decoy or non-targeting decoy were selected for hygromycin resistance.  
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Luciferase assay 
The TGF-ß-responsive Luciferase reporter SBE4-luc construct contains 4 
SMAD2/3/4 binding sites (SBE, SMAD binding element) regulating the expression of 
Luciferase (Addgene) (214).  
 
Gene-specific PCR primers were used to amplify from human genomic DNA the 3’ 
UTR for SMAD2 (base pairs 2619-5306), SMAD4 (base pairs 3804-6011), TGFBR1 (base 
pairs 2147-3947), and TGFBR2 (base pairs 537-2524). Using the appropriate restriction 
enzymes, these fragments were subcloned downstream of a Cytomegalovirus (CMV) 
promoter-driven Luciferase reporter (pMIR-REPORT vector, Ambion, Carlsbad, CA). 
Constructs were verified by sequencing. 
 
C3H/10T1/2 cells were plated at 25,000 cells/cm2. BioT transfection reagent 
(1.5ul:1μg DNA; Bioland Scientific, Paramount, CA) was used to co-transfect luciferase 
constructs containing the 3’ UTR of target mRNA, a constitutively active β-galactosidase 
construct (control for transfection efficiency), and miRNA hairpin inhibitors 
(Dharmacon/Thermo Fisher Scientific, Waltham, MA). 80 nM of anti-miR-433 or a 
negative control (non-targeting) miRNA inhibitors were used. Cells were serum deprived 
for 24 hours and cell lysates were analyzed for luciferase activity using the Luciferase 
Assay System (Promega) and normalized to β-Galactosidase using Galacton® (Life 
Technologies). Each luciferase experiment was performed at least 3 times, and each 
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experiment contained 6 biological replicates. More than one preparation of each DNA 
construct was tested. 
 
Western blot  
C3H/10T1/2 cells were plated at 300,000 cells/cm2 and treated with Doxycyline for 
24 hours in serum-free medium, to induce expression of the decoy. Cells were lysed with 
RIPA buffer containing Halt™ protease and phosphatase inhibitors (Thermo Fisher 
Scientific). A BCA assay (Thermo Fisher Scientific) was performed to quantify protein, 
and 20 µg protein was subjected to electrophoresis on a 10% SDS polyacrylamide gel. 
Proteins were transferred to a PVDF membrane (Millipore, Billerica, MA). Membranes 
were blocked with 5% BSA in TBS, 0.1% Tween. Rabbit anti-mouse phopho-SMAD2 
primary antibody (1:1000 Cell Signaling, Danvers, MA, Cat #138D4), rabbit anti-mouse 
SMAD2 primary antibody (1:1000 Cell Signaling, Cat #D43B4), rabbit anti-β-actin 
antibody (1:2000, Cell Signaling #13E5), and goat anti-rabbit horseradish peroxidase 
conjugated antibody (1:10000, Sigma Aldrich A0545) were used.  
 
 Quantitative real time PCR 
 RNA was isolated from cell cultures using TRIzol Reagent (Life Technologies), 
with added GlycoBlue Blue Coprecipitate (Life Technologies). RNA quality was 
determined using gel electrophoresis or an Experion High Resolution RNA Chip, 
assessing ribosomal bands 28S and 18S (Bio-Rad, Hercules, CA). RNA samples were 
additionally DNased using RQ1 DNase (Promega, Madison, WI). DNased RNA was 
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reverse-transcribed using Moloney murine leukemia virus-reverse transcriptase 
(Invitrogen, Carlsbad, CA). Gene expression was quantified by qPCR with iQ SYBR 
Green Supermix (Bio-Rad) and normalized to 18S rRNA levels. A cDNA standard curve 
was utilized to determine the relative quantity of gene expression. The primer sets used 
are shown in Table 4.5.  
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Table 4.5:  Primer sequences used for qPCR analysis.   
Gene (mouse) Sequence 
18S (sense) 
18S (antisense) 
5’-GCGTGTGCCTACCCTACGCC -3’ 
5’-ACGCAAGCTTATGGCCCGCA-3’ 
Ap (sense) 
Ap (antisense) 
5’-CCACTCGGGTGAACCACGCC -3’ 
5’-CCGCCACCCATGATCACGTCG -3’ 
Runx2 (sense) 
Runx2 (antisense) 
5’- CCTCTGGCCTTCCTCTCTCAGT -3’ 
5’- GCCACTCTGGCTTTGGGAAGAG -3’ 
Oc (sense) 
Oc (antisense) 
5′-TGGTGCACACCTAGCAGACAC -3′  
5′-CCGCTGGGCTTGGCATCTGT-3′ 
Sox9 (sense) 
Sox9(antisense) 
5′-ACGAAGCTGGCAGACCAGTA -3′  
5′-CGTTCTTCACCGACTTCCTC-3′ 
Col2a1 (sense) 
Col2a1 (antisense) 
5′-ACTGGTAAGTGGGGCAAGAC -3′  
5′-CCACACCAAATTCCTGTTCA -3′ 
ColXa1(sense) 
ColXa1 (antisense) 
5′-CTTTGTGTGCCTTTCAATCG -3′  
5′-GTGAGGTACAGCCTACCAGTTTT -3′ 
Cebpα (sense) 
Cebpα (antisense) 
5′-CAAGCCAGGACTAGGAGATT -3′  
5′-CCAAGGCACAAGGTTACTTC -3′ 
Pparγ (sense) 
Pparγ (antisense) 
5′-GAAATTACCATGGTTGAGACAGAG -3′  
5′-GTGAATGGAATGTCTTCATAGTG -3′ 
Fabp4 (sense) 
Fabp4 (antisense) 
5′-GGAACCTGGAAGCTTGTCTC -3′  
5′-TTCCTGTCGTCCTGCGGTGAT -3′ 
Gene (human) Sequence 
18S (sense) 
18S (antisense) 
5′-CCGATAACGAACGAGACTCTGG -3′  
5′-TAGGGTAGGCACACGCTGAGCC -3′ 
Sox9 (sense) 
Sox9 (antisense) 
5′-GGAACCTGGAAGCTTGTCTC -3′  
5′-TTCCTGTCGTCCTGCGGTGAT -3′ 
Col2a1(sense) 
Col2a1 (antisense) 
5′-CGTCCAGATGACCTTCCTACG -3′  
5′-TGAGCAGGGCCTTCTTGAG -3′ 
 
 
 microRNA expression levels were analyzed using the TaqMan MicroRNA Assay 
(Life Technologies). RNA was reverse transcribed with gene-specific primers to generate 
cDNA. microRNA expression was detected by qPCR and normalized to snoRNA 202 
levels. RNA experiments were performed at least twice and each experiment contained 
at least 4 biological replicates. Each sample was assayed in duplicate. 
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Micro CT 
Trabecular and cortical bone was measured by conebeam micro-focus x-ray 
computed tomography in male and female mice within the mid-diaphysis and distal 
metaphysis regions (µCT 40, Scanco Medical AG, Bassersdorf, Switzerland). Serial 
tomographic volumes were acquired at 55kV and 145µA, collecting 1000 projections per 
rotation at 300 µsec integration time. Three-dimensional 16-bit grayscale images were 
reconstructed using standard convolution back-projection algorithms with Shepp and 
Logan filtering, and rendered within a 12.3 mm field of view at a discrete density of 
578,704 voxels/mm3 (isometric 16-µm voxels). Segmentation of bone from marrow and 
soft tissue was performed in conjunction with a constrained Gaussian filter to reduce 
noise, applying hydroxyapatite-equivalent density thresholds of 300 mg/cm3 for cortical 
bone at 4 weeks, 200 mg/cm3 for trabecular compartments at 4 weeks, and 400 mg/cm3 
for cortical and trabecular compartments at 8 weeks. Volumetric regions for trabecular 
analysis were selected within the endosteal borders to include the secondary spongiosa 
of femoral metaphyses located 960 µm from the growth plate and extending 1 mm 
proximally. Trabecular morphometry was characterized be measuring the bone volume 
fraction (BV/TV), trabecular thickness, trabecular number, trabecular spacing, apparent 
density, tissue density, total volume, bone volume, and SMI. Cortical morphometry was 
characterized by length, sub-periosteal and sub-endosteal area, cortical mask, 
segmented bone, periosteal and endosteal perimeter, cortical porosity, and cortical 
thickness (215).  
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Statistics 
All data are shown as mean ± SEM, and are either a representative of 2 experiments 
containing 3 to 4 biological replicates per experiment; or pooled data from several 
experiments, representing 4 or more biological replicates. Details on biological replicates 
for each set of experiments are provided in the Figure Legends. Statistical significance 
was determined using two tailed ANOVA with Bonferroni post-hoc test or a Student’s t 
test as appropriate (KaleidaGraph, Synergy Software, Reading, PA).  
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CHAPTER 5 
Summary, Significance, and Conclusions 
 
Summary 
The overall goal of this work was to determine how miR-433 regulates cell 
signaling to impact lineage commitment and osteoblast function, thereby affecting the 
development, growth and maintenance of the skeleton. 
 
In our first study, we determined that miR-433 regulates the rhythm of the circadian 
clocks in vitro and in vivo. miR-433 displays a robust rhythmicity in murine calvaria, with 
peak expression just after light removal. 3’UTR luciferase reporter assays revealed that 
miR-433 directly targets 2 rhythmically expressed osteoblast genes, Igf1 and Hif1α, the 
regulation of which was confirmed by qRT-PCR analysis. miR-433 regulated the phase 
of Bmal1 and Per2 mRNA expression synchronized cells in vitro, and as well as Igf1 and 
Hif1α rhythmicity. To determine potential mechanisms underlying miR-433 regulation of 
the circadian clocks, we examined the ability of miR-433 to regulate glucocorticoid 
signaling, an important pathway for entrainment of the circadian clocks in vivo. Indeed, 
inhibition of miR-433 enhanced glucocorticoid signaling, measured by induction of direct 
glucocorticoid receptor transcriptional targets Dusp1 and Per2. Although miR-433 inhibits 
mRNA expression of the glucocorticoid receptor (both GRα and GRβ isoforms), it did not 
alter total glucocorticoid receptor protein levels.  
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Therefore, to further investigate the mechanism of miR-433 regulation of circadian 
clocks, we examined glucocorticoid receptor localization. Inhibition of miR-433 increased 
nuclear localization of glucocorticoid receptor when ligand was present, suggesting that 
it attenuates glucocorticoid sensitivity by limiting the residence of the glucocorticoid 
receptor in the nucleus.  
 
To confirm and extend our results to the in vivo setting, we developed a transgenic 
mouse model in which the miR-433 decoy, contained within the 3’ UTR of the red 
fluorescent reporter gene tdTomato, was expressed under the control of a 3.6 kb fragment 
of the rat Col1a1 promoter. In these mice, the miR-433 is expressed primarily in 
osteoblastic cells. In murine calvaria, expression of the miR-433 decoy increased the 
amplitude of Bmal1 and Per2 mRNA rhythm, and decreased Runx2 and osteocalcin 
mRNA. Overall, miR-433 regulates the expression of circadian clock genes in osteoblasts 
and dampens glucocorticoid signaling, likely contributing to the maintenance of circadian 
rhythm. 
 
In our second study, we examined the role of miR-433 in regulating TGF-β 
signaling and the impact on lineage commitment of mesenchymal progenitor cells. miR-
433 inhibits TGF-β signaling at least in part by targeting the 3’UTR of SMAD2 and 
TGFBR1. Inhibition of miR-433 activity in the presence of TGF-β induced SMAD2 protein 
levels and SMAD2 phosphorylation.  
 
119 
 
Since TGF-β is an important growth factor for initiation of osteogenic and 
chondrogenic differentiation, we examined miR-433 expression during lineage 
commitment of mesenchymal bone marrow stromal cells, to ascertain its possible role. 
During osteogenic differentiation, miR-433 expression decreased substantially, and miR-
433 inhibitor experiments showed that miR-433 is a negative regulator of osteogenic 
marker gene expression and calcium deposition. During adipogenic differentiation, miR-
433 expression did not change, nor did it play a role in regulating adipogenesis. miR-433 
expression robustly increased during chondrogenic differentiation of murine 
mesenchymal bone marrow stromal cells and a human fibroblast-derived mesenchymal-
like induced pluripotent stem cell line. miR-433 inhibitor experiments showed that miR-
433 restrained chondrogenic differentiation, as indicated by chondrocyte gene marker 
expression. In vivo, inhibition of miR-433 activity in osteoblasts decreased trabecular 
volume in growing male mice, suggesting that in the complex microenvironment of a 
whole animal, miR-433 plays an important role in regulating signaling pathways that 
promote bone formation and/or indirectly limit bone resorption.  
 
Significance 
Overall, this is the first study examining miRNA mediation of osteoblast circadian 
rhythm and provides further evidence of miRNA regulation of the entrainment of circadian 
clocks in other tissues. Since miR-433 levels in bone peak when circulating glucocorticoid 
levels are high, it likely plays a role in balancing the glucocorticoid response. We 
speculate that miR-433 can modify responsiveness of peripheral tissues to variations in 
circulating glucocorticoids and alter bone metabolism. These findings provide an added 
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dimension to our understanding of the mechanisms regulating glucocorticoid 
responsiveness, circadian rhythm, and their potential impact on the skeleton, and could 
have wide ranging impacts in other tissues.  
 
Although it is well appreciated that microRNAs regulate bone development and 
homeostasis, the molecular mechanisms by which many microRNAs regulate these 
processes are still not well understood. We identified miR-433 as a negative regulator of 
TGF-β signaling, an important pathway that promotes osteogenesis through recruitment 
of osteoprogenitors, as well as an important inducer of chondrogenesis. In this study, we 
provided new insights into miR-433 regulation of osteoblast differentiation and function in 
vitro and in vivo. In addition, we have determined that miR-433 shows differential 
expression patterns across 3 different lineages, although the molecular mechanisms 
regulating of miR-433 transcription in these tissues remains largely undetermined. We 
also identified 4 novel targets of miR-433: Igf1, Hif1α, SMAD2, and TGFBR1. These 
findings add to our understanding of how miRNAs regulate differentiation and their impact 
on skeletal development and remodeling. 
 
Systemic glucocorticoids are commonly used to treat inflammatory disease, but 
they can have detrimental side effects. Indeed, systemic administration of glucocorticoids 
is the most common cause of secondary osteoporosis (216). Prolonged glucocorticoid 
excess can also lead to the development of glucose intolerance, diabetes, and other 
metabolic disorders. This study provides important information on how miR-433 regulates 
GR signaling, which could provide new strategies for ameliorating some of the negative 
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effects of glucocorticoid therapies. In addition, since miR-433 also limits TGF-β signaling, 
this miRNA may play a role in skeletal diseases where TGF-β signaling is altered, as in 
the case of Loeys-Dietz or Marfan syndromes. A thorough understanding of miR-433 
function and its biological impact on the bone and cartilage in vivo could contribute to the 
development of therapeutics aimed at augmenting bone formation and/or cartilage repair.  
 
Increasing evidence suggests that miRNA-based therapeutics have strong 
potential, because their chemistry and stability can be altered to improve their function 
(217,218). For example, Miravirsen is a locked nucleic acid (LNA) anti-sense 
oligonucleotide targeting miR-122 (Santaris Pharma). It is currently in Phase 2 clinical 
trials for the treatment of hepatitis. Miravirsen is designed to suppress miR-122-mediated 
protection of the nucleolytic degradation of hepatitis C virus (HCV), providing a 
mechanism for repressing HCV infection and blocking replication (219).  
 
An additional microRNA based therapeutic, MRX34, is currently in Phase 1 trials 
for the treatment of selected solid malignancies (miRNA Therapeutics, Inc). MRX34 
contains double stranded RNA mimics for miR-34a, a microRNA that is downregulated in 
cervical, ovarian, colon, and lung cancers (220). miR-34a has been found to directly target 
several oncogenes which play a role in cell cycle and apoptosis, including cyclin 
dependent kinase 4 (CDK4), B cell lymphoma 2 (BCL2), and Wnt 1/3, (220). MRX34 
compound consists of the double stranded miR-34 mimic encapsulated in a liposome 
nanoparticle carrier, which is designed to enhance uptake by cancer cells (220,221).  
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Perhaps the greatest barrier to miRNA-based therapeutic is the ability to target 
them to the appropriate tissues. Recently, a system for targeting small RNAs to bone 
formation surfaces was reported. It consists of 8 aspartate repeats conjugated with a 
liposome containing miRNA inhibitors. The aspartate repeats enhance the binding of the 
liposome to crystalized hydroxyapatite surfaces found at sites of bone formation (222). 
These clinical trials and continued advances in the targeting miRNA-based therapeutics 
to the bone compartment provide a strong basis for future work on the use of miRNA 
based therapeutics to treat skeletal disorders.  
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Conclusion 
Overall, miR-433 is a potent inhibitor of glucocorticoid and TGF-β signaling, and 
restrains osteogenic and chondrogenic differentiation in vitro. Although miR-433 
decoyCol1a1 mice have decreased trabecular bone volume, they display increased mRNA 
for Runx2 and osteocalcin, as well as SMAD2. The interaction of pathways targeted by 
miR-433 in the context of the complex in vivo environment give rise the skeletal phenotype 
we observe, and the underlying mechanisms need to be identified.  
 
miRNAs target multiple mRNAs and can lead to substantial changes in signaling, 
therefore their effects can be wide ranging and diverse within an organism. The utilization 
of in vitro models to study molecular mechanisms of regulation, combined with in vivo 
models to understand phenotypic alterations, are critical for a three-dimensional 
understanding of bone physiology and the role of miRNAs. These findings add to our 
understanding of how miRNAs regulate differentiation and their impact on skeletal 
development and remodelling.  
 
Currently, our lab is investigating the phenotype of the miR-433 decoyCol1a1 mice, 
to understand how miR-433 affects bone formation. It remains to be investigated whether 
glucocorticoid or TGF-β signaling is altered in bone from miR-433 decoyCol1a1 mice. The 
implications of miR-433 regulation of circadian rhythm could have wide ranging impacts 
on skeletal cells, including effects on metabolism. The circadian clocks primarily function 
to maintain energy metabolism, to match peak metabolic action with physical activity. In 
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addition, the circadian clocks coordinate tissue repair, and could potentially play a role in 
fracture healing, although that has yet to be investigated.  
 
To investigate the role of miR-433 of cartilage in vivo, we developed a mouse 
transgenic mouse model in which the miR-433 decoy, contained within the 3’ UTR of the 
red fluorescent reporter gene tdTomato, was expressed under the control a Col2a1 
promoter. We currently have 4 founders, and plan to investigate the phenotype of these 
transgenic mice. We predict mice will have elongated growth plates, induced cartilage 
formation, and enhanced mineralization, as well as enhanced TGF-β signaling. Since 
Runx2 promotes chondrocyte hypertrophy, and miR-433 targets Runx2, we may see 
earlier progression towards hypertrophy in transgenic mice. miR-433 has been linked to 
a form of dominant X-linked chondrodysplasia in which a HDAC6 3’ UTR variant causes 
a change in miR-433 seed region targeting (135). It is possible that targeting of HDAC6 
by miR-433 could contribute to its actions in chondrogenic differentiation, by affecting 
acetylation levels of HDAC6 clients.  
 
In conclusion, much remains to be elucidated about the role of miR-433 in cartilage 
and bone, yet our research has made significant strides towards adding to our current 
understanding. We have identified mechanisms and targets, pointing the way to pathways 
to be investigated using in vivo models.  
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